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associated	with	 several	 undeniable	 disadvantages	 that	may	 have	 a	 long-lasting	 impact	 on	
the	patients’	quality	of	life.	Therefore,	peripheral	nerve	regeneration	and	repair	is	an	active	
field	of	 research	with	 a	 variety	of	 treatment	 strategies.	However,	most	of	 them	 fail	 to	be	
translated	into	clinical	practice.	Objective:	The	aim	of	the	present	thesis	was	to	investigate	
translational	 approaches	 for	 enhancing	 peripheral	 nerve	 regeneration	 as	 well	 as	 for	 the	
surgical	 nerve	 repair.	 Methods:	 The	 first	 manuscript	 of	 this	 thesis	 focused	 on	 the	
neurotrophic	 potency	 of	 adipose	 derived	 stem	 cells	 (ASC)	 in	 response	 to	 growth	 factors	
stimuli,	 i.e.	 NGF	 or	 VEGF	 in	 vitro	 and	 in	 vivo,	 and	 the	 impact	 of	 two	 different	 stem	 cell	
delivery	strategies,	i.e.	intramural	versus	intraluminal	loading,	in	fibrin	nerve	conduits	(FNC)	
on	 early	 nerve	 regeneration.	 The	 second	manuscript	 evaluated	 the	 neurotrophic	 effect	 of	
ASC	after	stimulation	by	a	variety	of	neurotrophic	factors	(NTF),	i.e.,	NGF,	BDNF,	NT3,	NT4,	
GDNF	 and	 CNTF,	 and	 investigated	 the	 neuroregenerative	 events	 taking	 place	 in	 ASC	 and	
sensory	 neuronal	 cells	 upon	 stimulation.	 In	 the	 third	 manuscript,	 we	 conducted	 a	
prospective,	randomized,	two-arm-controlled	phase-1	clinical	trial	comparing	the	outcome	of	
digital	nerve	injuries	with	or	without	nerve	gap	after	experimental	treatment	with	the	fibrin	
nerve	 conduit	 (FNC)	 or	 the	 epineural	 suture	 with	 fibrin	 sealant	 versus	 the	 standard	
treatment	 with	 the	 autologous	 nerve	 graft	 or	 the	 epineural	 suture	 over	 a	 period	 of	 12	
months.	Results:	NTF-stimulated	ASC	promoted	the	axonal	regeneration	in	vitro	and	in	vivo,	
with	 NT3-stimulation	 revealing	 a	 specifically	 significant	 effect.	 Analysis	 of	 regenerative	
events	 taking	 place	 in	 ASC	 and	 sensory	 neuronal	 cells	 upon	 NT3-signaling	 resulted	 in	 up-
regulation	of	regeneration	associated	genes	and	changing	phosphorylation	sites	in	both	cell	
types.	 FNC	 based	 intramural	 delivery	 of	 NGF-stimulated	 ASC	 promoted	 better	 axonal	
regeneration	in	vivo	than	intraluminal	delivery.	In	the	clinical	context,	the	FNC	and	the	fibrin	
sealant	may	enhance	the	early	nerve	regeneration	and	performed	non-inferior	to	standard	
treatments	 for	peripheral	nerve	 repair.	Conclusion:	Ex-vivo	 stimulation	of	ASC	by	NTF	and	











































cord:	 the	 ventral	 root	 extends	 from	 motor	 neurons	 whose	 cell	 bodies	 are	 found	 in	 the	
ventral	 horn	 of	 the	 spinal	 cord.	 The	
dorsal	 root	 comes	 from	 sensory	
neurons	whose	 cell	 bodies	 lie	 in	 the	
dorsal	 root	 ganglions.	 Peripheral	
nerves	 are	 the	 connecting	 structure	
between	 the	 central	 nervous	 system	
and	 distal	 sensory	 and	 motor	 target	
organs.	 The	 smallest	 functional	 unit	
of	 a	 nerve	 is	 the	 axon,	 a	 long	
cytoplasmic	 extension	 coming	 from	









Injuries	 to	 peripheral	 nerves	 are	 a	 common	 clinical	 problem	which	 experience	 increasing	
incidence.	Typical	patients	affected	are	young	males	with	a	mean	age	around	30	years	[4–6].	
Most	of	the	injuries	are	caused	by	motor	vehicle,	domestic	or	work	related	accidents	[4,5,7,8]	
due	 to	 transection,	 compression,	 traction	 and	 laceration	 mechanisms	 [7,9].	 Despite	
significant	 advances	 in	 microsurgical	 techniques	 and	 the	 patient-centered	 follow-up,	 the	









condition,	 resulting	 from	traction	or	compression	of	 the	nerve.	 It	 leaves	a	physically	 intact	
nerve,	 but	 the	 mechanical	 stress	 acting	 on	 the	 conductive	 structures	 may	 still	 cause	
impairment	of	motor	and	sensory	functions	[7].	With	the	correct	treatment,	 it	regenerates	
spontaneously.	 In	 axonotmesis,	 the	 axons	 and	 the	 myelin	 sheath	 are	 damaged,	 but	 the	
endoneurium,	 perineurium	 and	 epineurium	 remain	 intact.	 Thus,	 also	 here	 spontaneous	
healing	is	possible	[15].	However,	neurotmesis	is	a	complete	transection	of	the	nerve	with	its	






unfavorable	 environment	 [9,18,19],	 the	 adult	 peripheral	 nerve	 system	 displays	 the	
astonishing	ability	to	support	neuronal	survival	and	axonal	regeneration	after	nerve	 injury.	




adequate	 medical	 treatment	 and	 follow-up	 period	 [10,20].	 Severed	 nerve	 fibers	 will	
degenerate	within	24	to	48	hours	after	the	injury	[16].	In	case	of	axotomy,	the	distal	nerve	
end	 undergoes	 a	 process	 called	 Wallerian	 degeneration,	 which	 was	 first	 described	 by	
Augustus	Waller	in	1850	[9].	Calcium	influx	into	the	injured	axons	activates	axonal	proteases,	
which	 degenerate	 the	 axoplasm	 and	 axolemma	 [9].	 Schwann	 cells	 (SC)	 dedifferentiate,	
switching	from	myelinating	or	non-myelinating	cells	to	a	regenerative	phenotype	[21].	These	





the	 first	 node	of	Ranvier	 [16].	 Retrograde	 signaling	 along	 the	proximal	nerve	end	 initiates	
metabolic	modifications	in	the	perikaryon,	which	prepares	for	physiological	regeneration	[9].	
Regeneration	associated	pathways	are	activated	in	the	neuronal	body,	which	upregulate	the	
transcription	 of	 structural	 proteins	 such	 as	 beta-tubulin	 3	 and	 actin.	 These	 proteins	 are	
transported	to	the	injury	site	where	they	form	the	axonal	growth	cone	with	its	lamellipodiae	
and	filopodiae	for	axon	elongation	and	path	finding	[9,22,23].	Bands	of	Büngner	are	formed	
by	 SC,	 which	 act	 as	 regenerative	 tubes,	 guiding	 the	 outsprouting	 axons	 by	 providing	
extracellular	 adhesion	 molecules	 and	 chemotactic	 cues	 [24].	 The	 axons	 elongate	 in	 the	
direction	of	their	target	at	a	rate	of	about	1	mm	per	day,	and	are	remyelinated	with	shorter	
internodes	 [1,9,16].	 However,	 delayed	 nerve	 repair	 or	 very	 proximal	 injury	 may	 lead	 to	
chronic	axotomy	and	SC	denervation	[1].	Chronic	denervation	begins	around	3	months	after	
injury	and	is	characterized	by	a	lack	of	neuronal	contact	and	a	failure	of	SC	to	maintain	a	pro-
regenerative	 microenvironment	 [20,25].	 Chronically	 denervated	 SC	 down-regulate	 the	
expression	of	neurotrophic	factors	and	undergo	apoptosis	[22,26,27].	Depleted	from	trophic	
support,	 also	 the	 neuronal	 cell	 body	 and	 the	 distal	 nerve	 stump	 undergo	 molecular	 and	
morphological	 changes.	 Regeneration	 associated	 genes	 are	 down-regulated	 in	 the	
perikaryon,	which	 undergoes	 apoptotic	 death,	 and	 the	 distal	 nerve	 stump	 is	 colonized	 by	
atrophic	 SC	 and	 fibroblasts,	 finally	 leading	 to	 failure	 of	 target	 re-innervation	 [27].	 Also	
Figure	 2.	 Degeneration	 and	 regeneration	 after	
peripheral	 nerve	 injury.	 (A)	 Normal	 neuron	 and	 nerve	
fiber.	 (B)	 Wallerian	 degeneration	 after	 axotomy.	 The	
distal	 axon	 and	 myelin	 sheaths	 are	 fragmentated,	
Schwann	 cells	 dedifferentiate	 into	 a	 regenerative	
phenotype	 and	 proliferate,	 macrophages	 invade	 the	
distal	 nerve	 segment	 and	 help	 to	 phagocytose	 debris.	
(C)	 Schwann	 cells	 line	 up	 in	 bands	 of	 Büngner	 in	 the	
distal	nerve	segment.	The	axonal	growth	cone	extends	
lamellipodia	and	filopodia	which	advance	depending	on	
the	 different	 attractive	 and	 repulsive	 cues	 such	 as	
gradients	 of	 diffusible	 neurotrophic	 factors	 or	






motor	 and	 sensory	 functions	 are	 common	 consequences	 of	 failed	 regeneration	 [28].	 The	
target	 organ	 atrophies,	 followed	 by	 fibrosis	 of	 muscle	 fibers.	 The	 chance	 for	 functional	






In	 sharp	 and	 clean	 nerve	 dissections	 with	 minimal	 loss	 of	 tissue	 where	 a	 tension-free	
coaptation	 is	 possible,	 standard	 end-to-end	 neurorrhaphy	 with	 epineural	 suturing	 is	
performed	 [29,30].	 Proper	 alignment	 of	 internal	 nerve	 fascicles	 and	 epineural	 vasculature	
results	 in	 better	 outcome	 [1,16].	 However,	 epineural	 sutures	 create	 sites	 of	 inflammation	
and	 increased	 scarring,	 which	 are	 likely	 to	 hinder	 axonal	 regeneration	 [31].	 Thus,	 the	
concept	 of	 suture-less	 nerve	 repair	 was	 proposed	 [31].	 Several	 studies	 investigated	 the	
stabilizing	 effect	 of	 fibrin	 hydrogel	 on	 nerve	 coaptations	 [32,33],	 resulting	 in	 mixed	
outcomes.	Equivalent	reliability	and	even	superior	outcomes	of	suture-less	coaptations	due	
to	 decreased	 inflammation	 and	 scar	 tissue	 formation	 were	 observed	 by	 some	 authors	
compared	to	the	standard	epineural	repair	[34–36].	Others	reported	on	insufficient	stability	
provided	 by	 the	 fibrin	 gel,	which	 led	 to	 gapping	 or	 even	 disconnection	 of	 the	 nerve	 ends	
[37,38].	 A	 valid	 compromise	 might	 be	 to	 perform	 a	 minimum	 of	 epineural	 sutures	 with	
stabilization	of	the	suture	site	by	fibrin	sealant.	This	technique	resulting	in	increased	tensile	





free	 coaptation,	 the	 treatment	 of	 choice	 is	 the	 interposition	 of	 an	 autologous	 nerve	 graft	
[43–45].	Donor	nerves	are	dispensable	sensory	nerves	such	as	the	sural,	or	the	medial	and	
lateral	 antebrachial	 nerve	 [1].	 The	 interposed	 nerve	 autograft	 undergoes	 Wallerian	






surgery	 site	 is	 created,	which	not	only	 carries	 the	 risk	of	 surgery-associated	 complications	
and	 suboptimal	healing,	but	which	also	prolongs	 surgery	 time.	At	 the	 recipient	 site,	nerve	
size	 mismatch,	 and	 fibrosis	 from	 sutures	 and	 tissue	 handling	 may	 lead	 to	 unsatisfying	
regeneration	[1,16].		
The	nerve	 transfer	presents	a	surgical	alternative	 to	 the	nerve	 repair.	The	principle	of	 this	




In	 contrast	 to	 nerve	 grafting,	 in	 the	 nerve	 transfer	 usually	 only	 one	 neurorrhaphy	 site	 is	
needed,	and	it	minimizes	the	regeneration	distance	for	outsprouting	axons	in	order	to	reach	
and	re-innervate	the	end	organ	[1].	 If	 transferred	successfully,	the	recovered	function	may	
even	 be	 similar	 to	 the	 original	 muscle	 function.	 The	 outcome	 is	 enhanced	 if	 pure	 motor	




In	 order	 to	 overcome	 the	 disadvantages	 of	 the	 autologous	 nerve	 graft,	 several	 different	
autologous	 tissues	 have	 been	 investigated	 in	 the	 past	 for	 serving	 as	 a	 guiding	 structure.	
These	 include	 veins,	 arteries,	 skeletal	 muscles	 and	 tendons	 [7,11].	 Despite	 reports	 about	
positive	outcomes,	the	use	of	these	alternatives	never	experienced	a	breakthrough	in	clinical	
practice.	 Mostly	 because	 of	 limited	 availability,	 complicated	 harvesting	 and	 their	 little	










Another	 intensively	 investigated	 treatment	 alternative	 to	 nerve	 autografts	 are	 nerve	
conduits	(NC).	NC	are	tubular	structures	used	to	bridge	nerve	gaps.	After	attaching	the	nerve	
ends	 intraluminally,	 the	 NC	 not	 only	 guides	 outsprouting	 axons,	 but	 also	 provides	
mechanical	 stability	and	prevents	 invasion	of	myofibroblasts	and	 thus	excessive	 fibrosis	at	
the	 injury	 site	 [20,50].	 In	 the	 past,	 attention	was	 given	 to	 synthetic	 conduits	 out	 of	 non-
degradable	materials	with	silicone	being	clinically	 investigated	[51,52].	However,	due	to	 its	
non-degradable	 nature	 compression	 symptoms,	 increased	 scarring	 and	 irritation	 at	 the	
wound	site	have	been	described.	Furthermore,	a	second	surgery	was	needed	to	remove	the	
conduit	[1,11,53].	Thus,	current	conduits	are	made	of	biodegradable	polymers,	which	can	be	
produced	 from	a	 large	 variety	 of	 natural	 or	 synthetic	 sources	 [45],	 e.g.	 collagen,	 alginate,	
chitosan,	 silk	 fibroin	 and	 fibrin	 glue,	 lactic	 acid	 (PLA),	 glycolic	 acid	 (PGA),	 γ-hydroxybutyric	
acid	(PHB),	and	ε-caprolactone	(PCL).		The	significant	advantage	of	using	NC		for	nerve	repair	
is	 to	 avoid	 the	 sacrifice	 of	 a	 healthy	 nerve	 and	 a	 second	 surgery	 site,	 easier	 surgery	
technique,	reduced	surgery	time	and	thus	cost	effectiveness	[54].	However,	the	challenge	is	
to	 choose	 the	 proper	material	 for	 a	 good	 conduit	 design.	 Several	 FDA-	 and	 CE-	 approved	
“off-the-shelf”	conduits	are	already	commercially	available	for	clinical	use	[7,55].	Thus,	the	
optimal	NC	has	not	yet	been	found.	Such	a	conduit	would	need	to	incorporate	several	crucial	
characteristics	 such	 as	 1)	 easy	 handling	 and	 adaptability,	 2)	 biocompatibility,	 3)	 flexible	
consistency	with	good	mechanical	 stability,	4)	 selective	permeability	 for	 regeneration-	and	





commercially	 available	 [32,58].	 In	 the	 surgical	 practice	 fibrin	 gel	 is	 widely	 accepted	 as	
hemostat,	 sealant	 and	 adhesive	 and	has	 shown	excellent	 biocompatibility	 [53,58–61].	 The	
two	 main	 components	 of	 fibrin	 gel	 are	 a	 thrombin	 solution	 with	 calcium	 chlorid,	 and	 a	
fibrinogen	 solution	 with	 or	 without	 factor	 XIII	 and	 fibronectin,	 and	 an	 anti-fibrinolytic	
stabilization	 agent	 such	 as	 aprotinin	 [61–63].	 The	 bio-mechanical	 properties	 of	 fibrin	 glue	





of	 fibrin	gel	were	successful	 in	supporting	short-	and	 long-term	nerve	regeneration	 in	vivo	




Following	 the	 example	 of	 nerve	 autografts,	 regeneration	 over	 a	 critical-sized	 nerve	 gap	
would	also	require	a	favorable	microenvironment	within	the	conduit,	which	would	be	able	


















(B)	 The	 engineered	 bioartificial	 nerve	 conduit	 as	 an	 alternative	 nerve	 repair	 strategy.	 Such	 a	 conduit	 from	







NTF	 have	 been	 studied	 extensively	 for	 their	 important	 role	 during	 neuronal	 development	
and	 after	 nerve	 injury	 [69].	 Physiologically,	 a	 basal	 expression	 of	 trophic	 signals	 is	
maintained	by	non-neuronal	cells	in	order	to	ensure	a	homeostatic	state	for	intact	sensory,	
motor	and	autonomic	neurons	 [22].	 Following	nerve	 injury,	 a	 range	of	NTF	 from	neuronal	
and	 non-neuronal	 sources	 [23]	 is	 immediately	 upregulated	 for	 the	 support	 of	 neuronal	
survival,	 axonal	 regeneration	 and	 target	 organ	 re-innervation	 [7,22,69].	 	 There	 are	 three	
main	 families	 of	 NTF:	 First,	 the	 neurotrophins,	 the	 probably	 most	 well-studied	 group,	 to	
whom	belong	NGF,	BDNF,	NT3	and	NT4/5.	Second,	the	GDNF	family	of	neurotrophic	factors	
ligands	with	GDNF,	neurturin,	artemin,	and	persephin.	And	third,	the	neuropoetic	cytokines	
which	 generally	 refer	 to	molecules	 of	 the	 interleukin-6	 family	 and	 include	 IL-6,	 IL-11,	 LIF,	
oncostatin	M,	CNTF,	 cardiotrophin-1,	neuropoietin	and	cardiotrophin-like	cytokine	 [70,71].	





thus	 delivery	method	 of	 soluble	NTF	 from	NC	 to	 the	 injury	 site.	 Controlled	 and	 sustained	
release	of	NTF	seems	to	be	desirable,	even	though	the	optimal	dosing	may	depend	on	the	
specific	growth	factor	[22,73,74].	Different	delivery	strategies	exist	to	address	this	question:	
NTF	 incorporated	 into	 engineered	micro-	 or	 nanovesicles,	 nanofiber	 scaffolds	 or	 polymer	










regeneration	 in	 various	 studies	 [24,48,75,83].	 However,	 painful	 nerve	 biopsy	 and	 the	
sacrifice	of	 a	healthy	nerve	are	 required	of	 the	patient	 in	order	 to	harvest	 autologous	SC.	
This	 is	 followed	 by	 rather	 challenging	 culture	 conditions	 in	 order	 to	 obtain	 sufficient	
amounts	 of	 transplantable	 cells,	 which	 results	 in	 significant	 treatment	 delay	 [84,85].	
Therefore,	 the	 idea	 for	 stem	 cell-based	 therapies	 emerged,	 where	 therapeutic	 stem	 cells	
should	be	easily	accessible	and	proliferate	rapidly	in	culture.		
It	 was	 discovered	 that	MSC	 from	 bone	marrow	 sources	 can	 be	 induced	 into	 SC-like	 cells	
(SCLC)	 under	 specific	 stimuli	 and	enhance	peripheral	 nerve	 regeneration	 [86–89].	 To	 their	
disadvantage,	 their	harvest	 requires	painful	biopsy	as	well;	 this	 is	why	attention	 turned	 to	
MSC	obtained	 from	adipose	 tissue	 [90,91].	Adipose	 tissue	has	been	demonstrated	 to	be	a	
clinically	viable	source	of	multipotent	cells,	so	called	adipose-derived	stem	cells	(ASC),	which	
can	be	harvested	in	abundant	quantity	from	liposuction	or	abdominoplasty	procedures	[91–
93].	ASC	also	meet	 the	 requirements	of	 fast	 and	uncomplicated	proliferation	 [92]	 and	are	
able	to	differentiate	towards	mesenchymal	and	non-mesenchymal	 lineages	similar	to	bone	
marrow-derived	MSC	 (BMSC)	 [91,94,95].	 In	 culture	over	 several	passages,	ASC	 retain	 their	
mesenchymal	 stem	 cell	 properties	 and	 express	 a	 low	 immunogenic	 profile	 due	 to	 low	
expression	 of	 MHC	 class	 II	 antigens	 [96,97],	 which	 makes	 them	 suitable	 for	 allogeneic	
transplantation.	 Furthermore,	 they	 secrete	 an	 array	of	 neurotrophic	 factors	 and	 cytokines	
[98–101]	and	can	be	differentiated	towards	a	SC-like	phenotype	(SCLC),	expressing	markers	
such	 as	 S-100	 and	 glial	 fibrillary	 acidic	 protein	 [98,99,101,102].	Direct	 comparison	of	 SCLC	
derived	from	BMSC	or	ASC	and	SC	in	vivo	showed	similar	potency	for	all	three	cell	types	in	
supporting	nerve	regeneration	[85].	However,	a	significant	disadvantage	limiting	the	clinical	
use	 of	 SCLC	 is	 the	 lengthy	 differentiation	 process,	 which	 requires	 up	 to	 three	 weeks.	
Furthermore,	it	has	been	shown	that	SCLC	derived	from	ASC	rapidly	return	to	stem	cell-like	
characteristics	after	withdrawal	of	the	differentiation	medium	[103].	Thus,	applicability	and	
relevance	 of	 SCLC	 for	 the	 clinical	 routine	 might	 be	 questioned,	 especially	 since	 several	
studies	suggest	a	similar	therapeutic	potential	for	ASC	and	SCLC	derived	from	ASC	[104–106].	
There	are	two	possible	mechanisms	explaining	the	regenerative	potency	of	ASC	in	response	
to	 local	 stimuli	 at	 the	 nerve	 injury	 site:	 The	 first	 hypothesis	 suggests	 in	 vivo	 trans-
differentiation	 of	 ASC	 into	 SCLC	 [102,105,107,108].	 The	 other	 hypothesis	 sees	 the	
neurotrophic	potential	of	ASC	in	their	secretome,	which	contains	a	wide	range	of	molecular	
factors	 [98,100,109].	 Furthermore,	 transplanted	 ASC	 may	 enhance	 recruitment	 of	
	 18	
endogenous	 SC	 to	 the	 injury	 site	 [104].	 Thus,	 there	 is	 a	 clear	 need	 for	 exploring	 the	
regenerative	capacity	of	ASC	involving	only	minimal	manipulation	procedures	in	vitro	[8].	
Another	 line	 of	 research	 represents	 the	 delivery	 of	 cells	 within	 a	 NC.	 For	 the	
transplantation	of	cells	to	the	injury	sites,	NC	can	be	used	as	scaffolds	for	cell	seeding	[24].	
Biological	 extracellular	 matrices	 such	 as	 fibrin,	 collagen,	 laminin	 and	 fibronectin	 provide	
structural	support	 for	stem	cell	adhesion	[24,110,111].	Stem	cells	 loaded	 in	fibrin	scaffolds	
were	able	to	adhere,	spread	and	proliferate	[112–114].	However,	the	most	optimal	delivery	
system	 remains	 to	 be	 determined.	 Particularly	 for	 FNC	 only	 few	 methods	 have	 been	
evaluated	 and	 no	 systematic	 comparison	 was	 reported	 so	 far.	 One	method	 is	 to	 inject	 a	
fibrin	solution	loaded	with	cells	intraluminally	[115].	An	alternative	approach	is	to	integrate	





Gold	 standard	 treatments	 for	 the	 peripheral	 nerve	 repair	 have	 experienced	 immense	
improvements	through	advanced	microsurgical	techniques.	However,	these	procedures	are	
associated	 with	 inevitable	 co-morbidities.	 Thus,	 multiple	 lines	 of	 research	 have	 emerged	
with	 the	 aim	 to	 tackle	 these	 challenges	 with	 a	 variety	 of	 approaches	 targeting	 different	














This	MD-PhD	work	 aimed	 at	 investigating	 the	 potential	 of	 novel	 strategies	 for	 peripheral	
nerve	 repair	 and	 regeneration.	 Ex-vivo	 stimulation	 of	 ASC	 by	 NTF	 might	 present	 an	
innovative	 approach	 for	 stem	 cell-based	 therapies.	 Furthermore,	 fibrin	 hydrogel	 is	 a	
promising	biomaterial	which	provides	 a	 suitable	 scaffold	 for	 stem	 cell	 delivery.	 It	 has	 also	
been	 used	 successfully	 in	 shape	 of	 NC	 for	 bridging	 nerve	 gap-injuries	 in	 vivo.	 However,	
neither	has	the	most	beneficial	delivery	route	been	established	yet,	nor	has	the	suitability	of	
FNC	been	evaluated	for	clinical	use.	The	present	thesis	explores	these	questions	in	different	








Objective	 1:	 Providing	 a	 comparative	 in	 vitro	 assay	 analyzing	 the	 neurotrophic	 potency	 of	
ASC	in	response	to	stimulation	by	NGF,	BDNF,	NT3,	NT4,	GDNF	or	CNTF.	




patient	 satisfaction	 for	 the	 experimental	 (epineural	 suture	 with	 fibrin	 sealant)	 repair	
compared	to	the	standard	(epineural	suture)	repair	with	a	one-year	follow-up	after	surgery.		
Objective	 2:	 In	 critical-sized	 nerve	 gap	 digital	 injuries,	 proving	 non-inferiority	 in	 clinical	















person	 for	 the	management	and	conduct	of	 this	 study.	 I	prepared	 the	present	manuscript	
and	will	continue	to	work	on	this	clinical	trial	until	its	completion	and	publication.	






















































Peripheral	 nerve	 injuries	 often	 result	 in	 lifelong	 disabilities	 despite	 advanced	 surgical	
interventions,	indicating	the	urgent	clinical	need	for	effective	therapies.	In	order	to	improve	
the	potency	of	adipose-derived	stem	cells	 (ASC)	 for	nerve	 regeneration,	 the	present	 study	
focused	primarily	on	ex-vivo	stimulation	of	ASC	by	using	growth	factors,	 i.e.,	nerve	growth	




























Peripheral	nerve	 injuries	often	result	 in	 loss	of	sensory	and	motor	 functions	due	to	 lack	of	
effective	 therapeutic	 strategies,	 thus	 there	 is	 a	 great	 clinical	 need	 for	 developing	 new	
therapies	 [118,119].	 Schwann	 cells	 (SC)	 play	 a	 crucial	 role	 in	 neuronal	 survival,	 axonal	
regeneration	 and	 re-myelination	 [22,81]	 by	 secreting	 an	 array	 of	 molecular	 signals,	
neurotrophic	factors	(NTF)	and	extracellular	matrix	proteins	[82].	Furthermore,	SC	generate	
bands	of	Büngners	 for	 topographical	 guidance	 and	path	 finding	of	 the	 regenerating	 axons	
[92].	However,	the	therapeutic	use	of	SC	is	hampered	due	to	the	problems	associated	with	
harvesting	 the	 cells	 from	 healthy	 nerves	 and	 resulting	 co-morbidities	 [85].	 Therefore,	 the	
need	for	stem	cell-based	therapies	emerged	for	treating	nerve	injuries.	
Therapeutic	 stem	 cells	 should	 be	 easily	 accessible	 and	 undergo	 rapid	 proliferation	 and	
differentiation	 in	 vitro	 under	 controlled	 conditions.	 Mesenchymal	 stem	 cells	 (MSC)	 can	
differentiate	 into	 SC-like	 cells	 (SCLC)	 under	 specific	 stimuli	 and	 enhance	 peripheral	 nerve	
regeneration	 [86–89].	Not	 limiting	 to	 the	 source	of	 bone	marrow,	MSC	with	multi-lineage	
capacity	 can	 also	 be	 obtained	 from	 adipose	 tissue,	 dental	 pulp,	 umbilical	 cord	 blood	 and	
Wharton’s	jelly	of	umbilical	cord	[90,91,120,121].	Adipose-derived	stem	cells	(ASC)	are	easily	
accessible	in	large	quantities	from	fat-tissue	enabled	by	liposuction	or	abdominoplasty	[91–
93].	 ASC	 proliferate	 rapidly	 [92]	 and	 possess	 a	 multi-lineage	 capacity,	 i.e.,	 adipocytes,	
osteoblasts,	chondrocytes	[91,94,122].	Furthermore,	ASC	retain	their	mesenchymal	potency	
over	long-term	culture	[92,122]	and	promote	the	nerve	regeneration	similar	to	bone	marrow	
stem	cells	 [85].	 In	allogeneic	transplantation,	usage	of	ASC,	 like	any	other	adult	stem	cells,	
benefits	 from	 their	 hypo-immunogenicity	 or	 immune-privilege	 by	 virtue	 of	 the	 reduced	
expression	of	HLA-DR	class	II	histocompatibility	antigens	[96,97].	Thus,	ASC	may	enable	the	




regeneration	 both	 in	 vitro	 and	 in	 vivo.	When	 co-cultured	with	motor	 neuron-like	 cells	 or	
dorsal	 root	 ganglion	 (DRG)	 sensory	 neurons,	 ASC	 enhanced	 the	 neurite	 number	 and	
outgrowth	length	[102,123,124].	In	line	with	these	findings,	several	animal	studies	reported	
enhanced	 axonal	 regeneration	 and	 sensory-motor	 nerve	 conduction,	 when	 ASC	 were	
transplanted	 in	 polymeric	 nerve	 conduits	 (NC)	 or	 fibrin-hydrogel	 nerve	 conduits	 (FNC)	
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[116,125,126].	Improved	axonal	growth	and	elongation	was	found	in	FNC	loaded	with	ASC	in	
comparison	to	empty	FNC	[115,125,127].	However,	 the	optimal	delivery	 route	 for	ASC	still	
remains	to	be	established	in	the	context	of	peripheral	nerve	reconstruction.	Various	studies	
involving	ASC	therapy	employed	different	cell	delivery	routes,	i.e.,	injection	into	the	lumen,	
dispersion	within	 the	 fibrin	 conduit	wall,	 dispersion	within	 the	 lumen	of	 fibrin	matrix	 and	
coating	on	the	 luminal	surface	 [85,104,115–117,123].	However,	 the	therapeutic	efficacy	of	
the	cells	was	scarcely	correlated	with	delivery	routes	and	the	carrier	matrix	in	the	context	of	
nerve	regeneration.	Thus,	the	ineffective	and	incomplete	outcome	achieved	so	far	by	using	
the	ASC	 therapy	can	be	 largely	attributed	 to	various	 structural	and	biochemical	aspects	of	
the	 microenvironment	 at	 the	 injury	 site	 that	 were	 inadequately	 orchestrated	 through	
different	 delivery	 routes.	 Moreover,	 studies	 focusing	 on	 the	 understanding	 of	 the	
spatiotemporal	 influence	 of	 the	 cell	 carrier	matrix	 on	 the	 efficacy	 of	 therapeutic	 cells	 are	
largely	missing.	Therefore,	 there	 is	a	clear	need	to	 investigate	systematically	the	 impact	of	
important	 local	 cell	 delivery	 strategies	 on	 nerve	 regeneration	 and	 to	 establish	 effective	
options.	
The	 most	 important	 soluble	 factors	 known	 to	 support	 the	 neuronal	 survival	 and	 axonal	
regeneration	 following	 traumatic	 nerve	 injury	 are	 NTF	 [7,20,22,76].	 Nerve	 growth	 factor	
(NGF),	 amongst	 other	 NTF,	 specifically	 promotes	 survival	 and	 regeneration	 of	 sensory	
neurons	 by	 binding	 to	 the	 high-affinity	 trk-A	 receptors	 [74].	 Vascular	 endothelial	 growth	
factor	 (VEGF)	 on	 the	 other	 hand	 is	 a	 potent	 angiogenic	 factor,	 which	 promotes	 the	
proliferation	of	endothelial	cells,	and	the	formation	and	permeability	of	vascular	structures	
[128].	 Nevertheless,	 several	 studies	 demonstrated	 VEGF	 for	 having	 neurotrophic	 activities	
that	were	mediated	either	by	flk-1	and	flt-1	receptor	binding	or	by	enhanced	vascularization	
[128–131].	
Same	 as	 for	 ASC,	 various	 studies	 reported	 on	 improved	 nerve	 regeneration	 supported	 by	
exogenously	administered	NTF	[74,76,78,132].	Despite	these	findings,	the	growth-promoting	
effects	of	ASC	in	response	to	a	specific	growth	factors’	stimulus	largely	remain	elusive	in	the	
context	 of	 nerve	 regeneration.	 However,	 rapid	 upregulation	 of	 NGF	 and	 VEGF	 after	
traumatic	 nerve	 injury	 [7,22]	 clearly	 indicates	 the	 clinical	 significance	 for	 exploring	 the	
therapeutic	 impact	 of	 ASC	 following	 growth	 factors’	 stimulation	 in	 the	 context	 of	 axonal	
regeneration.	
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We	 hypothesize	 an	 improvement	 in	 the	 neurotrophic	 capacity	 of	 ASC	 in	 response	 to	




The	 influence	of	 the	 stem	cell	 delivery	 route,	 i.e.,	 FNC	assisted	 intramural	 vs.	 intraluminal	





All	 in	 vitro	 studies	were	 conducted	 in	 accordance	with	 the	 local	 veterinary	 commission	 in	
Basel,	 Switzerland	 (No.	 2925).	 Visceral	 adipose	 tissue	 was	 harvested	 from	 adult	 Sprague-
Dawley	rats	and	processed	under	sterile	conditions	as	described	earlier	[102].	Briefly,	the	fat	
tissue	was	rinsed	in	0.01	M	phosphate-buffered	solution	(PBS),	minced,	and	resulting	tissue	
was	 digested	 with	 0.15%	 (w/v)	 Type	 I	 Collagenase	 (Gibco	 Life	 Technologies,	 Cat.	 No.	
17100017)	for	1	h	at	37	°C	and	centrifuged	for	5	min	at	1500	rpm	and	4	°C.	The	pellet	was	re-
suspended	in	growth	medium	(GM)	i.e.,	Dulbecco`s	Modified	Eagle`s	Medium	(DMEM,	Gibco,	
Cat.	 No.	 41965039)	 supplemented	 with	 10%	 Foetal	 Bovine	 Serum	 (PAN-Biotech,	 EU-







Rat	 ASC	 (P2)	 were	 seeded	 on	 24-well	 plates	 for	 characterization.	 Cells	 were	 fixed	 in	 4%	
paraformaldehyde	 (PFA)	 at	 room	 temperature	 (RT)	 for	 10	 min	 and	 permeabilized	 and	
blocked	in	1%	normal	goat	serum	(NGS)	in	PBS	(i.e.,	dilution	buffer)	for	60	min	at	RT.	ASCs	
were	 incubated	 overnight	 at	 4	 °C	 with	 the	 human	 mesenchymal	 stromal	 cell	 markers	
monoclonal	mouse	 anti-CD44	 (1:1000),	monoclonal	mouse	 anti-CD90	 (1:200),	monoclonal	
mouse	anti-CD105	(1:200)	and	monoclonal	rabbit	anti-CD29	(1:100),	and	the	hematopoietic	
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marker	 polyclonal	 rabbit	 anti-CD45	 (1:500)	 (Abcam,	 Cat.	 No.	 ab93758).	 Cells	 were	 then	
washed	in	PBS	and	incubated	for	60	min	at	RT	with	the	secondary	antibody	goat	anti-mouse	
Alexa	 Fluor	 488	 (1:500,	 Abcam,	 Cat.	 No.	 ab150109)	 and	 goat	 anti-rabbit	 Alexa	 Fluor	 488	
(1:500,	 Abcam,	 Cat.	 No.	 ab150061),	 and	 Hoechst	 33258	 nuclear	 staining	 (1:1000,	 Sigma	
Aldrich,	 Cat.	No.	 94403).	 Subsequently,	 digital	 images	were	 acquired	 at	 20×	magnification	
(numerical	 aperture	 0.45)	 by	 using	 a	 Nikon	 Eclipse	 Ti2	 fluorescent	 inverted	 microscope	
(Nikon	Eclipse	Ti2-E,	-E/B,	Nikon	Corporation,	Japan)	and	a	Photometrics	prime	95B	25	mm	
camera	(Teledyne	photometrics,	Tucson,	AZ,	USA).	The	 images	were	automatically	stitched	
by	 the	Nikon	NIS-Elements	AR	 image	analysis	 software	 (NIS-	Elements	AR	Analysis	5.11.00	
64-bit,	 Laboratory	 Imaging,	 spol.	 s.r.o.,	 Praha,	 Czech	 Republic).	 Furthermore,	




Fertilized	 chicken	 eggs	 were	 obtained	 from	 Gepro	 Geflügelzucht	 AG	 (Flawil,	 Switzerland).	
The	eggs	were	shipped	at	ambient	temperature	and	incubated	at	37.8	±	0.2	°C	under	100%	
relative	 humidity	 for	 10	 days	 (E10).	 After	 incubation,	 the	 eggs	 were	 cleaned	 with	 70%	
ethanol	 and	opened	under	a	 laminar	airflow	cabinet	 to	 collect	 the	embryos.	 E10	embryos	
were	 dissected	 following	 a	 standard	 dissection	 protocol	 under	 a	 stereomicroscope	 [74].	





with	 or	 without	 supplementation	 of	 exogenous	 growth	 factors,	 i.e.,	 10	 ng/mL	 of	
recombinant	human	NGF	or	recombinant	mice	VEGF,	as	indicated	in	the	experimental	design.	








As	 illustrated	 in	 Figure	 1,	 ASC	were	 stimulated	 by	NGF	 (NGF-ASC)	 or	 VEGF	 (VEGF-ASC)	 or	
without	growth	factor	(ASC)	for	72	h	and	resulting	conditioned	medium	(CM),	i.e.,	CM-NGF-
ASC,	CM-VEGF-ASC	and	CM-ASC	was	subsequently	used	 for	DRG	assay	 for	48	h.	When	the	






were	maintained	 in	 a	 humid	 atmosphere	 at	 37	 °C	 and	 5%	CO2	 for	 48	 h	 and	 images	were	
Figure 1. Ex-vivo stimulation of adipose stem cells using growth factors, and fibrin-hydrogel nerve conduits’ assisted stem cell delivery













After	 48	 h,	 DRG	 cultures	were	 observed	 under	 a	microscope	 and	 bright-field	 images	with	
phase-contrast	 were	 taken	 at	 5x	 magnification	 using	 a	 Zeiss	 Axio	 Vert.A1	 inverted	
fluorescent	microscope	 (Carl	 Zeiss	 AG,	 Jena,	 Germany)	 and	 a	 Zeiss	 AxioCam	MRc	 camera	
(Carl	Zeiss	AG,	 Jena,	Germany).	DRG-explants	were	 then	 fixed	 in	4%	PFA	at	RT	 for	10	min,	
and	then	permeabilized	and	blocked	 in	PBS	containing	0.1%	Triton	X-100	and	1%	BSA	(i.e.,	
dilution	 buffer)	 for	 60	min	 at	 RT.	 For	 immunocytochemistry,	 the	 cultures	were	 incubated	
overnight	with	the	following	primary	antibody	at	4	°C:	monoclonal	mouse	anti-β-Tubulin	III	
(1:1000,	Sigma-Aldrich,	Cat.	No.	T8578)	for	axons.	The	cultures	were	then	washed	in	PBS	and	
incubated	 with	 the	 following	 secondary	 antibody:	 sheep	 anti-mouse	 Cy3	 (1:500,	 Sigma	
Aldrich,	Cat.	No.	C2181)	and	Hoechst	33258	nuclear	staining	(1:1000,	Sigma	Aldrich,	Cat.	No.	





DRG-explant	 cultures	 were	 analyzed	 for	 axonal	 length	 and	 axonal	 area	 in	 an	 automated	
manner	with	a	standardized	analysis	mask	created	using	the	Nikon	NIS-Elements	AR	image	
analysis	 software.	 The	 DRG	 area	 was	 defined	 in	 the	 Hoechst	 channel	 and	 the	 intensity	
threshold	was	set	to	be	45.	The	area	occupied	by	axonal	outgrowth	was	evaluated	in	the	Cy3	
















fibrinogen	 100	 mg/mL,	 factor	 XIII	 0.6–10	 IU/mL,	 plasminogen	 40–120	 mg/mL,	 aprotinin	
synthetic	 3000	 KIU/mL,	 and	 a	 thrombin	 solution	 500	 IU/mL	 with	 calcium	 chloride	 40	
μmol/mL.	Fibrin	conduits	measuring	14	mm	in	length,	1	mm	in	wall	thickness	and	2	mm	in	
lumen	were	produced	for	bridging	a	10	mm	nerve	gap-injury.	The	thrombin	500	IU/mL	was	
diluted	 in	 sterile	 water	 to	 30	 IU/mL.	 Equal	 amounts	 of	 the	 diluted	 thrombin	 and	 the	






the	 conduit,	 the	 resulting	 fibrin	 conduits	 were	 designated	 as	 FNC-W(NGF-ASC)	 and	 FNC-
W(ASC)	 respectively.	 Immediately	 before	 transplantation,	 cells	 were	 trypsinized	 and	
suspended	in	a	volume	of	540	μL	Fibrinogen.	Further,	60	μL	of	thrombin	solution	30	IU/mL	
















and	 randomly	 categorized	 into	 6	 groups:	 1)	 autograft,	 2)	 fibrin-hydrogel	 nerve	 conduit	
without	 cells,	 i.e.,	 FNC,	3)	 FNC	assisted	 intramural	delivery	of	unstimulated	ASC,	 i.e.,	 FNC-
W(ASC),	4)	FNC	assisted	intramural	delivery	of	NGF-stimulated	ASC,	i.e.,	FNC-W(NGF-ASC),	5)	
FNC	 assisted	 intraluminal	 delivery	 of	 unstimulated	 ASC,	 i.e.,	 FNC-L(ASC),	 6)	 FNC	 assisted	
intraluminal	 delivery	of	NGF-	 stimulated	ASC,	 i.e.,	 FNC-L(NGF-ASC).	All	 surgical	 procedures	
were	 performed	 under	 general	 anesthesia	 with	 3%	 isoflurane.	 Routinely,	 Buprenorphine	




the	 conduit	 by	 a	 single	 epineural	 suture	 (9/0	 nylon,	 S&T).	Muscles	 and	 fascia	 layers	were	
closed	 with	 a	 single	 resorbable	 stitch	 (5/0	 Vicryl,	 Ethicon)	 and	 the	 skin	 was	 closed	 by	 a	









embedded	 in	 OCT	 freezing	 media	 (Tissue-Tek,	 Sakura,	 Japan)	 and	 flash-frozen	 in	 liquid	
nitrogen	 through	 2-methylbutane	 (Sigma	 Aldrich,	 Cat.	 No.	M32631).	 Nerve	 cross-sections	
were	prepared	by	cryostat	from	the	middle,	distal	and	far	distal	part	of	the	explanted	nerve	
tissue	 as	 shown	 in	 Figure	 2.	 The	 middle	 sections	 were	 taken	 right	 in	 the	 middle	 of	 the	
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explanted	conduit,	 the	distal	 sections	at	 the	distal	 suture	point,	and	the	 far	distal	 sections	
5mm	distal	to	the	distal	suture.	Serial	5	μm	thick	tissue	sections	were	prepared	onto	slides	
(Superfrost	plus,	Menzel-Gläser,	Braunschweig,	Germany)	and	stored	at	−80	°C.	For	staining,	
every	second	section	was	processed.	First,	 the	slides	were	 fixed	 in	4%	PFA	 for	10	min	and	
washed	in	distilled	water	and	then	blocked	using	dilution	buffer	for	60	min	at	RT.	Slides	were	
then	incubated	overnight	at	4	°C	with	the	following	primary	antibodies:	monoclonal	mouse	
anti-β-Tubulin	 III	 (1:1000,	 Sigma	 Aldrich,	 Cat.	 No.	 T8578)	 and	 polyclonal	 rabbit	 anti-S100	
(1:100,	 abcam,	 Cat.	 No.	 ab76729).	 After	 rinsing	 in	 PBS,	 secondary	 sheep	 anti-mouse	









and	 used	 for	 quantitative	 analysis	 of	 anatomical	 structures.	 For	 measuring	 the	 axonal	
density	 and	 area	 occupied	 by	 SC,	 an	 automated	 program	 was	 performed	 using	 the	
standardized	 analysis	 mask	 created	 by	 Nikon	 NIS-Elements	 AR	 image	 analysis	 software.	
Axonal	 count	and	nerve	area	values	were	used	 for	 calculation	of	axonal	density.	 Similarly,	
the	area	occupied	by	SC	was	given	in	reference	to	the	nerve	area.	
	
Figure 2. Anatomical segmentation
representing the histological analysis
of the reconstructed nerves.
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2.15.	Statistical	Analysis	
Data	 were	 analyzed	 by	 two-way	 analysis	 of	 variance	 (ANOVA)	 following	 Bonferroni	





ASC	 were	 isolated,	 cultured,	 and	 resulting	 cells	 were	 characterized	 phenotypically	 by	
immunocytochemistry.	ASC	were	found	to	be	positive	for	mesenchymal	marker	CD29	(87%),	







and	1.05	±	0.37	 (Figure	3B	and	3C).	 In	 contrast	 to	NGF,	 stimulation	with	VEGF	or	without	
growth	 factors	 (no	 GF)	 resulted	 in	 only	minimal	 axonal	 length,	 i.e.,	 85	 ±	 55	 and	 66	 ±	 45	
(Figure	3B),	which	are	consistent	with	axonal	area	measurements,	i.e.,	0.14	±	0.10	and	0.10	±	
0.05	(Figure	3C)	respectively.	
Interestingly,	 CM-NGF-ASC	enhanced	 the	 significant	 axonal	 outgrowth,	 i.e.,	 657	±	224	and	
1.76	±	0.65	(Figure	3D	and	3E).	In	the	case	of	CM-ASC,	no	significant	axonal	outgrowth	could	
be	observed,	i.e.,	80	±	56	and	0.083	±	0.039	(Figure	3F).	Together	these	observations	clearly	
indicate	 the	 significantly	enhanced	potency	of	ASC	 in	 response	 to	 the	NGF-stimulation	 for	
promoting	axonal	regeneration	in	vitro	(Figure	3D,	3E	and	3F).	
In	 contrast	 to	NGF	 conditions,	 CM-VEGF-ASC	did	not	 result	 in	 the	 enhancement	of	 axonal	
outgrowth,	 i.e.,	 161	 ±	 55	 and	 0.111	 ±	 0.032	 (Figure	 3E).	 These	 observations	 indicate	 no	
significant	 improvement	 of	 ASC’s	 potency	 in	 response	 to	 VEGF-stimulation	 for	 supporting	
axonal	regeneration	in	vitro	(Figure	3D,	3E	and	3F).	
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In	 line	 with	 CM-NGF-ASC,	 CM-ASC+NGF	 culture	 condition	 resulted	 in	 a	 robust	 axonal	












Figure 3. Axonal outgrowth from DRG-explants in vitro. (A) Microphotographs of DRG-explant cultures treated with growth factors. (B)
Quantitative measurements of axonal length (µm). (C) Quantitative measurements of the axonal area (mm2). (D) Microphotographs of DRG-
explant cultures that were treated with conditioned medium (CM) derived from unstimulated ASC (CM-ASC) or NGF-stimulated ASC (CM-NGF-
ASC) or VEGF-stimulated ASC (CM-VEGF-ASC). (E) Quantitative measurements of axonal length (µm). (F) Quantitative measurements of the
axonal area (mm2). (G) Microphotographs of DRG-explant cultures that were treated with ASC’s CM in combination with exogenous NGF (CM-
ASC+NGF) or VEGF (CM-ASC+VEGF). (H) Quantitative measurements of axonal length (µm). (I) Quantitative measurements of the axonal area
(mm2). The red staining is !-Tubulin III+ for regenerating axons. For images (A)–(I), the scale bar represents 500 μm and the bars represent the










As	 depicted	 in	 Figure	 4,	 histological	 recovery	 of	 the	 treated	 animals	 was	 measured	 by	
analyzing	the	β-Tubulin	III+	axons	(Figure	4	and	5)	and	S100	+	SC	structures	(Supplementary	
Figure	S2A,	B)	from	the	middle,	distal	and	far-distal	parts	of	the	regenerated	nerve	tissue.	In	





intramural	 stem	 cell	 delivery	 was	 evident	 compared	 to	 the	 intraluminal	 delivery	 route	
(Figure	4	and	5).	Together,	these	results	reveal	the	autograft	matching	performance	of	NGF-
stimulated	 ASC	 in	 combination	 with	 the	 intramural	 delivery	 route	 i.e.,	 FNC-W(NGF-ASC).	
Furthermore,	the	general	tendency	of	enhanced	axonal	regeneration	supported	by	the	FNC-





Group Axonal Length (µm) Axonal Area (mm2) 
no GF 0.066	±	0.045 0.099	±	0.049 
NGF 0.307	± 0.110 1.051	±	0.371 
VEGF 0.085	±	0.055 0.141	±	0.095 
CM-ASC 0.080	±	0.056 0.083	±	0.039 
CM-NGF-ASC 0.657	±	0.224 1.760	±	0.649 
CM-VEGF-ASC 0.161	±	0.055 0.111	±	0.032 
CM-ASC+NGF 0.569	±	0.086 1.976	±	0.527 
CM-ASC+VEGF 0.181	±	0.051 0.215	±	0.077 
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In	 contrast	 to	 the	 distinct	 axonal	 growth	 response	 (Figure	 4	 and	 5)	 found	 for	 the	 various	





Figure 4. Fibrin assisted delivery of (stimulated) ASC for nerve regeneration. Microphotographs showing the !-Tubulin III+ axons for
various experimental groups: Autograft; empty fibrin-hydrogel nerve conduit “FNC”; FNC’s wall loaded with unstimulated ASC, i.e.,
intramural ASC delivery “FNC-W(ASC)”; FNC’s lumen loaded with unstimulated ASC, i.e., intraluminal ASC delivery “FNC-L(ASC)”; FNC’s
wall loaded with NGF-stimulated ASC, i.e., intramural NGF-ASC delivery “FNC-W(NGF-ASC)”; FNC’s lumen loaded with NGF-stimulated





We	 hypothesized	 impactful	 change	 in	 the	 ability	 of	 ASC	 in	 response	 to	 growth	 factors’	
stimuli	for	supporting	the	axonal	regeneration.	Therefore,	the	present	study	was	designed	to	
investigate	 the	 growth	 promoting	 capacity	 of	 ASC	 following	 NGF-	 or	 VEGF-stimulation	 in	
vitro	and	to	further	translate	in	vitro	findings	into	animals	in	combination	with	two	different	
cell	 delivery	 approaches,	 i.e.,	 FNC	 assisted	 intramural	 vs.	 intraluminal	 ASC	 loading	 for	
studying	 the	 early	 nerve	 regeneration.	 In	 the	 present	 study,	 experiments	were	 conducted	
using	 NGF-	 or	 VEGF-stimulated	 ASC.	 A	 large	 portion	 of	 the	 research	 investigating	 the	
neurotrophic	effect	of	ASC	involved	SCLC	derived	from	ASC	while	studies	on	undifferentiated	
ASC	remained	scarce	[8,82].	Although	an	SCLC	phenotype	seems	to	be	desirable	for	optimal	
regenerative	 support,	 2	 to	 4	 weeks	 of	 in	 vitro	 differentiation	 process	 represents	 a	major	
obstacle	 for	 the	 clinical	 use	 of	 SCLC.	On	 the	 other	 hand,	 the	 therapeutic	 benefits	 of	 SCLC	
derived	 from	ASC	vs.	undifferentiated	ASC	are	 still	 not	 clear.	Nevertheless,	 several	 studies	
suggest	 a	 similar	 therapeutic	 potential	 for	 both	 cell	 types	 [104–106].	 There	 are	 two	
mechanisms	 explaining	 the	 regenerative	 potency	 of	 undifferentiated	 ASC.	 The	 first	
hypothesis	states	that	ASC	might	undergo	an	in	vivo	trans-differentiation	in	response	to	the	
regenerative	microenvironment	[102,105,107,108].	The	other	hypothesis	postulates	that	the	
neurotrophic	 potential	 of	 ASC	 may	 lie	 in	 the	 secretome	 containing	 a	 wide	 range	 of	
biochemical	and	molecular	factors	[109].	ASC	exosomes	releasing	miRNA21,	miRNA222	and	
Figure 5. Fibrin assisted delivery of
(stimulated) ASC for nerve regeneration.
Quantitative measurements of !-Tubulin
III+ axons for various experimental
groups: Autograft; empty fibrin-hydrogel
nerve conduit “FNC”; FNC’s wall loaded
with unstimulated ASC, i.e., intramural
ASC delivery “FNC-W(ASC)”; FNC’s lumen
loaded with unstimulated ASC, i.e.,
intraluminal ASC delivery “FNC-L(ASC)”;
FNC’s wall loaded with NGF-stimulated
ASC, i.e., intramural NGF-ASC delivery
“FNC-W(NGF-ASC)”; FNC’s lumen loaded
with NGF-stimulated ASC, i.e.,
intraluminal NGF-ASC delivery “FNC-
L(NGF-ASC)”. The bars represent the
mean ± SD of n = 6. Significant differences
at * p < 0.05 are indicated in comparison
to all other experimental groups.
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miRNAlet7a	play	an	important	role	in	neuronal	survival	by	inhibiting	apoptotic	pathways.	In	




(TGF-ß),	 and	 platelet-derived	 growth	 factors	 (PDGF)	 [98,101,133–135].	 Furthermore,	
transplanted	ASC	may	enhance	the	recruitment	of	endogenous	SC	to	the	injury	site	[104].	
To	the	factors	secreted	by	ASC,	adult	neurons	may	respond	differently	in	contrast	to	
embryonic	 neurons,	 as	 the	 trophic	 dependency	 of	 the	 various	 subsets	 of	 neurons	 in	 the	
peripheral	nervous	system	may	change	with	the	age.	However,	several	studies	have	shown	









culture	 conditions	 indicating	 the	 growth-promoting	 function	 of	 NGF	 in	 combination	 with	
ASC’s	CM.	However,	the	exact	mechanism	of	the	underlying	molecular	functions	needs	to	be	
determined	along	with	 the	analysis	of	 the	secretome	profile	of	ASC	 resulting	 from	various	
experimental	 stimuli.	On	 the	 contrary,	VEGF	 culture	 conditions	did	not	 result	 in	enhanced	






In	 agreement	 with	 our	 in	 vitro	 findings,	 NGF-stimulated	 ASC	 exhibited	 a	 potential	 for	
promoting	enhanced	early	nerve	regeneration	as	evidenced	by	the	increased	number	of	β-






In	 the	 middle	 of	 the	 fibrin	 conduit,	 i.e.,	 regenerated	 nerve	 tissue,	 the	 density	 of	
regenerating	axons	for	the	animals	treated	with	intramural	delivery	of	NGF-stimulated	ASC	
was	statistically	comparable	to	the	autograft	treatment,	 indicating	not	only	the	benefits	of	
stimulated	 stem	 cells	 but	 also	 the	 importance	 of	 the	 cell	 delivery	 route.	 However,	 the	
outcome	 in	 the	 subsequent	 distal	 and	 far-distal	 segments	was	 significantly	 higher	 for	 the	
autograft	group.	Further	on,	the	intramural	delivery	of	NGF-stimulated	ASC,	i.e.,	W(NGF-ASC)	





[137,138].	 On	 the	 other	 hand,	 studies	 reporting	 on	 sequential	 release	 of	 VEGF	 and	 NGF	
exhibited	 beneficial	 effects.	 However,	 the	 early	 axonal	 regeneration	 in	 those	 animals	
appeared	 poorer	 than	 in	 autograft	 animals	 as	 evidenced	 by	 significantly	 lower	 axonal	
regeneration	 in	 the	 middle	 graft	 after	 4	 weeks	 [139].	 Therefore,	 the	 regeneration	 levels	




distal	part	of	 the	nerve,	we	would	need	 to	 further	 refine	our	 technique	by	optimizing	 the	
loading	density	of	stem	cells	and	by	incorporating	topographical	guidance	structures.	Given	
the	focus	i.e.,	early	nerve	regeneration	of	the	present	study,	we	only	measured	early	axonal	
regeneration.	 However,	 the	 data	 and	 knowledge	 obtained	 in	 the	 present	 study	 create	 a	
strong	 rationale	 for	 further	 evaluations	of	 functional	 restoration,	 i.e.,	 behavioral	 recovery,	
electrophysiological	recovery	and	re-innervation	in	a	long-term	study.	
The	delivery	of	cells	within	a	conduit	is	a	subject	of	research	and	the	most	optimal	delivery	
system	 remains	 to	 be	 determined.	 Particularly	 for	 FNC,	 only	 a	 few	 methods	 have	 been	
evaluated	 separately	 and	 no	 systematic	 comparison	 was	 reported	 so	 far.	 In	 general,	 the	
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fibrin	 solution	 loaded	 with	 cells	 can	 be	 injected	 into	 the	 lumen	 of	 the	 FNC	 [115].	 An	







mm	 nerve	 gap-injury.	 It	 is	 widely	 accepted	 that	 fibrin	 hydrogels	 possess	 a	 macro	 porous	
structure	with	a	pore	size	of	10–20	μm	[140].	Therefore,	the	conduits	used	in	our	study	may	
possess	 pore	 sizes	 in	 the	 range	 of	 2–4	 μm	 and	 10–20	μm	 respectively	 for	 intramural	 and	
intraluminal	fibrin	structures	that	can	naturally	facilitate	the	diffusion	of	ASC	secretome.	ASC	
based	exosomes	and	microvesicles	are	in	the	range	of	a	sub-micrometer	size	(i.e.,	150	nm	to	
200	 nm)	 [109,141].	 Thus,	 the	 macro	 porous	 fibrin	 hydrogels	 enable	 easy	 passage	 of	
nanometer-sized	vesicles	and	related	soluble	factors.	However,	the	density	of	transplanted	
cells	within	 the	hydrogel	microenvironment	may	 account	 for	 different	 outcomes	 achieved	
through	different	delivery	routes	in	the	present	study.	In	the	case	of	the	intramural	delivery	




high	 concentrations	 of	 local	 growth	 factors.	 Thus,	 the	 highly	 enriched	 luminal	
microenvironment	 of	 the	 intraluminal	 delivery	 system	 may	 impede	 the	 speed	 of	 axonal	
regeneration	 in	contrast	 to	 the	 intramural	delivery	system.	Taken	together,	 the	underlying	
structural	and	cellular	factors	may	explain	appropriately	the	better	outcome	achieved	by	the	
intramural	cell	delivery	system	in	the	present	study.	
Fibrinogen	 concentrations	 used	 in	 the	 present	 study	 for	 both	 intramural	 and	 intraluminal	
constructs	were	based	on	our	earlier	research	work	and	no-detrimental	effects	were	found	
when	 the	 fibrin	 matrix	 was	 used	 alone.	 As	 we	 previously	 reported	 [104],	 ASC	 showed	
survival	 signals	up	 to	14	days	 after	 transplantation	 in	NC.	 These	 findings	 indicate	 that	 the	
regenerative	 effects	 of	 transplanted	 ASC	 are	 mediated	 by	 the	 initial	 boost	 of	 released	
growth	 factors.	The	cell	delivery	 route	dependent	outcome	observed	 in	our	present	 study	
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may	partly	be	attributed	to	the	potency	of	the	transplanted	cells.	Further	investigations	on	
the	 spatiotemporal	 profile	 of	 the	 transplanted	 ASC	may	 provide	 important	 understanding	







not	 VEGF,	 to	 promote	 axonal	 regeneration	 in	 vitro	 and	 in	 vivo.	 Furthermore,	 our	 study	
reveals	 the	 importance	 of	 a	 fibrin-hydrogel	 conduit	 assisted	 intramural	 delivery	 system	 in	
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Figure S1. Stem cell characterization. Immunostaining and characterization of rat adipose stem cells
(ASC) that are positve for mesenchymal stem cell markers CD44, CD 90, CD105 and CD29 in green.
ASC are negative for hematopoietic marker CD45. The blue staining is Hoechst indicating cell nuclei.
The scale bar represents 100 μm.
Figure S2A. Immunostaining of Schwann cell growth. Microphotographs showing the S100+ Schwann cell structures for the
experimental groups: Autograft; empty fibrin-hydrogel nerve con- duit “FNC”; FNC’s wall loaded with unstimulated ASC, i.e., intramural
ASC delivery “FNC-W(ASC)”; FNC’s lumen loaded with unstimulated ASC, i.e., intralumen ASC delivery “FNC-L(ASC)”; FNC’s wall loaded
with NGF-stimulated ASC, i.e., intramural NGF-ASC delivery “FNC-W(NGF-ASC)” and FNC’s lumen loaded with NGF-stimulated ASC, i.e.,















Figure S2B. Quantitative analysis of
Schwann cell growth. Measurement of
the S100+ Schwann cell structures for
the experimental groups: Autograft;
empty fibrin-hydrogel nerve conduit
“FNC”; FNC’s wall loaded with
unstimulated ASC, i.e., intramural ASC
delivery “FNC-W(ASC)”; FNC’s lumen
loaded with unstimulated ASC, i.e.,
intralumen ASC delivery “FNC-L(ASC)”;
FNC’s wall loaded with NGF-stimu-
lated ASC, i.e., intramural NGF-ASC
delivery “FNC-W(NGF-ASC)” and FNC’s
lumen loaded with NGF-stimulated
ASC, i.e., intraluminal NGF-ASC
delivery “FNC-L(NGF-ASC)”. The bars
represent the mean ± SD of n=6.
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We	 report	 on	 a	 potential	 strategy	 involving	 the	 exogenous	 neurotrophic	 factors	 (NTF)	 for	
enhancing	 the	 neurotrophic	 capacity	 of	 human	 adipose	 stem	 cells	 (ASC)	 in	 vitro.	 For	 this,	
ASC	were	stimulated	for	three	days	using	NTF,	i.e.,	nerve	growth	factor	(NGF),	brain-derived	
neurotrophic	factor	(BDNF),	neurotrophin	3	(NT3),	NT4,	glial	cell-derived	neurotrophic	factor	
(GDNF),	and	ciliary	neurotrophic	 factor	 (CNTF).	The	 resulting	 conditioned	medium	 (CM)	as	
well	 as	 individual	 NTF	 exhibited	 distinct	 effects	 on	 axonal	 outgrowth	 from	 dorsal	 root	
ganglion	(DRG)	explants.	 In	particular,	CM	derived	from	NT3-stimulated	ASC	(CM-NT3-ASC)	
promoted	robust	axonal	outgrowth.	Subsequent	transcriptional	analysis	of	DRG	cultures	 in	
response	 to	 CM-NT3-ASC	 displayed	 significant	 upregulation	 of	 STAT-3	 and	 GAP-43.	 In	
addition,	phosphoproteomic	analysis	of	NT3-stimulated	ASC	revealed	significant	changes	in	
the	phosphorylation	state	of	different	proteins	that	are	involved	in	cytokine	release,	growth	
factors	 signaling,	 stem	 cell	 maintenance,	 and	 differentiation.	 Furthermore,	 DRG	 cultures	
treated	 with	 CM-NT3-ASC	 exhibited	 significant	 changes	 in	 the	 phosphorylation	 levels	 of	
proteins	 involved	 in	 tubulin	 and	 actin	 cytoskeletal	 pathways,	 which	 are	 crucial	 for	 axonal	
growth	 and	 elongation.	 Thus,	 the	 results	 obtained	 at	 the	 transcriptional,	 proteomic,	 and	



















Peripheral	 nerve	 injuries	 with	 loss	 of	 functional	 tissue	 are	 a	 common	 clinical	 problem	
whereby	 patients	 suffer	 lifelong	 sensory-motor	 deficits	 in	 spite	 of	 advanced	microsurgical	
procedures	 and	 functional	 follow-ups	 [1,5,9,11].	 However,	 nerve	 injuries	 have	 no	 viable	
alternative	 to	match	 the	 regenerative	 level	of	 the	gold	 standard	 (autologous	nerve	grafts)	
[1,11,45].	Thus,	the	need	for	nerve	tissue	engineering	approaches	emerged.	
The	process	of	timely	and	effective	nerve	regeneration	is	primarily	influenced	by	the	
regenerative	 microenvironment,	 which	 comprises	 sustained	 growth	 factor	 release,	
permissive	extracellular	matrix	scaffolds,	and	Schwann	cells	facilitating	the	axonal	guidance	
[22,142].	Therefore,	the	unsatisfactory	clinical	outcomes	obtained	so	far	can	be	attributed	to	





neurotrophic	 factors	 (NTF),	 and	 support	 axonal	 path	 finding	 [25,81,143].	 SC	 express	 p75,	
TrkA,	 TrkB,	 TrkC,	 and	GFRα	 receptors	 [144–151],	which	 are	 responsive	 for	 various	 growth	
factors	and	rapidly	establish	paracrine	signaling	 in	response	to	endogenous	growth	factors	
[25,26,81,152].	 Several	 studies	 proved	 the	 beneficial	 effects	 of	 transplanted	 SC	 for	 nerve	
repair	 and	 axonal	 regeneration	 [48,75,83,153].	 However,	 the	 harvest	 of	 autologous	 SC	




grow	 fast,	 and	 have	 a	 low	 immunogenic	 profile	 [96,97].	 They	 secrete	 an	 array	 of	
neurotrophic	 factors,	 chemokines,	 and	miRNA	 [98–101]	and	can	be	differentiated	 into	SC-
like	 cells	 (SCLC)	 in	 order	 to	 improve	 their	 neurotrophic	 properties	 [98,99,101,102].	 ASC	
differentiation	 into	 SCLC	 requires	 extended	 stimulation	 involving	 a	 complex	 array	 of	
exogenous	 factors	 over	 up	 to	 three	weeks,	 indicating	 a	major	 hurdle	 to	 their	 clinical	 use.	
Moreover,	it	was	demonstrated	that	SCLC	rapidly	revert	to	fibroblast	cell-like	characteristics	
after	 the	 withdrawal	 of	 the	 differentiation	 medium.	 Therefore,	 their	 beneficial	 effects	
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severed	 nerves,	 i.e.,	 neurons	 and	 glial	 cells,	 require	 neurotrophic	 support	 and	 structural	
guidance	 for	 repair	 and	 regeneration	 [156].	 Although	 the	 peripheral	 nervous	 system	 is	
capable	 of	 spontaneous	 regeneration	 due	 to	 the	 intrinsic	 regenerative	 capacity,	 long-gap	
and	 chronic	 nerve	 injuries,	 in	 particular,	 require	 exogenous	 trophic	 and	 topographical	
support	 for	 effective	 regeneration	 [72].	 However,	 recent	 studies	 showed	 the	 deleterious	
effects	of	using	large	number	of	biological	factors	for	promoting	axonal	regrowth	while	the	
therapeutic	 benefits	 are	 being	 ineffective	 [157].	 Thus,	 the	 need	 for	 effective	 and	 viable	
alternatives	 such	 as	 cell	 therapies	 emerged	 [155].	 Cell	with	 improved	 trophic	 capacity	 for	




Growth	 factors	 and	 related	 receptors	 play	 key	 role	 in	 the	 SC	 lineage	 and	 their	 autocrine	
survival	loop	[159]	[52].	Interestingly,	ASC	were	found	to	express	most	of	the	receptors	for	
NTF	 [98,100,103,160–162]	 suggesting	 that	 ASC	 may	 operate	 like	 SC	 in	 response	 to	 NTF	
stimulation.	Within	this	context,	we	recently	demonstrated	enhanced	neurotrophic	capacity	
of	ASC	in	response	to	nerve	growth	factor	(NGF)	stimulation	in	vitro	and	in	vivo	[158].	
Given	 these	 facts,	 we	 hypothesized	 that	 NTF	may	 have	 a	 fundamental	 role	 in	 the	
neurotrophic	capacity	of	 the	stem	cells,	which	 is	 related	 to	SC	 lineage,	which	 in	 turn	 is	an	
important	topic	to	basic	neurobiology	(SC	lineage)	and	nerve	tissue	engineering.	Therefore,	
it	is	fundamental	to	understand	the	role	of	variety	of	NTF	individually	on	the	fate	of	ASC	at	
cellular	 and	 molecular	 levels.	 However,	 studies	 elucidating	 the	 influence	 of	 NTF	 on	 ASC	
biology	(neurotrophic	capacity)	are	 largely	missing,	thus	there	 is	a	great	need	for	shedding	
light	on	this	key	topic	[158].	
Therefore,	 in	 the	 present	 study,	 we	 have	 evaluated	 different	 NTF	 representing	
neurotrophins,	 i.e.,	 NGF,	 brain-derived	 neurotrophic	 factor	 (BDNF),	 neurotrophin	 3	 (NT3),	
and	NT4;	the	glial	cell-derived	neurotrophic	factor	(GDNF)	family	of	ligands,	i.e.,	GDNF,	and	
neurotrophic	 cytokines,	 i.e.,	 CNTF	 [22,69,70]	 for	 ex	 vivo	 stimulation	of	ASC.	 Subsequently,	
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we	assessed	the	axonal	growth-promoting	capacity	of	a	conditioned	medium	(CM)	derived	
from	NTF-stimulated	ASC	as	well	 as	 individual	NTF	and	 found	 significant	effects	on	axonal	
outgrowth.	Furthermore,	molecular	changes	taking	place	in	the	stimulated	ASC	as	well	as	in	





Adipose	 tissue	 was	 obtained	 from	 healthy	 patients	 undergoing	 elective	 liposuction	 or	
abdominoplasty.	All	patients	had	signed	an	informed	consent	form	prior	to	the	surgery.	The	
isolation	 of	 ASC	 was	 performed	 under	 sterile	 conditions	 according	 to	 a	 well-established	
protocol	 [102].	 The	 fat	 tissue	 was	 cleaned	 from	 erythrocytes	 by	 rinsing	 with	 0.01	 M	





Cat.	 No.	 P40-47500)	 and	 1%	 Penicillin/Streptomycin	 (BioConcept,	 Cat.	 No.	 4-01F00-H).	
Extracted	ASC	were	seeded	at	a	density	of	3000	cells/cm2	and	cultured	at	37	°C	with	5%	CO2	
in	a	humid	atmosphere	with	GM	being	changed	every	72	h.	Cell	passage	was	performed	at	




P2	human	ASC	were	 seeded	on	24-well	 plates	 for	 characterization.	 Cells	were	 fixed	 in	 4%	
paraformaldehyde	 (PFA)	 at	 room	 temperature	 (RT)	 for	 10	 min	 and	 permeabilized	 and	
blocked	in	PBS	containing	0.1%	Triton	X-100	and	1%	normal	goat	serum	(NGS)	(i.e.,	dilution	
buffer)	 for	 20	 min	 at	 RT.	 ASCs	 were	 incubated	 overnight	 at	 4	 °C	 with	 the	 human	
mesenchymal	 stromal	 cell	 markers	 monoclonal	 mouse	 anti-CD44	 (1:1000),	 monoclonal	
mouse	 anti-CD90	 (1:200),	monoclonal	mouse	CD105	 (1:200),	monoclonal	 rabbit	 anti-CD29	
(1:100)	and	polyclonal	rabbit	anti-CD45	(1:500)	(Abcam,	Cat.	No.	ab93758).	Cells	were	then	
washed	 in	 PBS	 and	 incubated	 for	 1	 h	 at	 RT	with	 the	 secondary	 antibody	 goat	 anti-mouse	
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Alexa	 Fluor	 488	 (1:500,	 Abcam,	 Cat.	 No.	 ab150109)	 and	 goat	 anti-rabbit	 Alexa	 Fluor	 488	
(1:500,	 Abcam,	 Cat.	 No.	 ab150061),	 and	 Hoechst	 33258	 nuclear	 staining	 (1:1000,	 Sigma	
Aldrich,	 Cat.	 No.	 94403).	 Subsequently,	 digital	 images	were	 acquired	 at	 20x	magnification	
(numerical	 aperture	 0.45)	 by	 using	 a	 Nikon	 Eclipse	 Ti2	 inverted	 fluorescent	 microscope	































with	 500	µl	 of	 volume	were	 stimulated	 either	 by	 rhNGF	 (NGF-ASC),	 rhGDNF	 (GDNF-ASC),	
rhBDNF	 (BDNF-ASC),	 rhCNTF	 (CNTF-ASC),	 rhNT3	 (NT3-ASC)	 or	 rhNT4	 (NT4-ASC)	 or	without	
neurotrophic	 factor	 (ASC)	 for	72	h.	Resulting	conditioned	medium	(CM),	 i.e.,	CM-NGF-ASC,	
CM-GDNF-ASC,	 CM-BDNF-ASC,	 CM-CNTF-ASC,	 CM-NT3-ASC,	 CM-NT4-ASC	 and	CM-ASC	was	
subsequently	 used	 for	 the	 DRG	 assay.	 As	 controls,	 culture	 conditions	 with	 growth	media	
supplemented	 with	 the	 respective	 NTF,	 i.e.	 NGF	 alone	 (NGF),	 GDNF	 alone	 (GDNF),	 BDNF	
alone,	 (BDNF),	 CNTF	 alone	 (CNTF),	 NT3	 alone	 (NT3),	 NT4	 alone	 (NT4),	 and	 the	 growth	
medium	 without	 NTF-supplementation	 (GM)	 were	 used.	 For	 all	 conditions	 neurotrophic	
factors	 were	 applied	 at	 10ng/ml	 based	 on	 preliminary	 experiments	 [74].	 Neurotrophic	
factors	were	purchased	from	R&D	Systems	Inc.,	Minneapolis,	USA	(Art.	No.	256-GF,	212-GD,	








After	 48	 h,	 bright	 field	 images	 with	 a	 phase	 contrast	 of	 DRG-explants	 were	 taken	 at	 5x	
magnification	 using	 a	 Zeiss	 Axio	 Vert.A1	 inverted	 fluorescent	 microscope	 (Carl	 Zeiss	 AG,	
Germany)	 and	a	 Zeiss	AxioCam	MRc	 camera	 (Carl	 Zeiss	AG,	Germany).	DRG-explants	were	
then	fixed	in	4%	PFA	at	RT	for	10	min	and	permeabilized	and	blocked	in	PBS	containing	0.1%	
Triton	X-100	and	1%	bovine	serum	albumin	(BSA)	(i.e.,	dilution	buffer)	for	20	min	at	RT.	For	
immunocytochemistry,	 the	 cultures	 were	 incubated	 overnight	 at	 4	 °C	 with	 the	 primary	
antibody	monoclonal	 mouse	 anti-β-Tubulin	 III	 (1:1000,	 Sigma-Aldrich,	 Cat.	 No.	 T8578)	 for	
regenerating	axons.	The	cultures	were	then	washed	in	PBS	and	incubated	for	1	h	at	RT	with	
the	 secondary	 antibody	 sheep	 anti-mouse	Cy3	 (1:500,	 Sigma	Aldrich,	 Cat.	No.	 C2181)	 and	
Hoechst	33258	nuclear	staining	(1:1000,	Sigma	Aldrich,	Cat.	No.	94403).	Digital	images	of	the	
stained	specimens	were	acquired	at	15x	magnification	 (numerical	aperture	0.45)	using	the	










DRG-explants	grown	 for	48	h	 in	NT3-stimulated	ASC’s	 conditioned	medium	 (CM-NT3-ASC),	
unstimulated	ASC’s	 conditioned	medium	 (CM-ASC),	NT3-supplemented	GM	 (NT3)	 and	GM	
only	 (GM)	were	 evaluated	 for	 up-regulation	 of	 the	 regeneration	 associated	 genes	 STAT-3	
and	GAP-43,	β-Actin	was	used	as	housekeeping	gene.	A	total	of	500	ng	RNA	per	sample	was	
converted	into	cDNA	following	the	protocol	for	the	SuperScript™	IV	VILO™	Master	Mix	with	
ezDNase™	 Enzyme	 (Invitrogen™,	 Cat.	 No.	 11766050)	 and	 using	 the	 SimpliAmp™	
Thermocycler	 (Applied	 Biosystems™	 A24811	 by	 life	 technologies,	 Thermo	 Fisher	 Scientific	
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AG,	 Switzerland).	 Amplification	 was	 performed	 with	 the	 QuantStudio™	 3	 Real-Time	 PCR	
Systems	 (applied	 biosystems,	 Thermo	 Fisher	 Scientific	 AG,	 Switzerland)	 using	 Fast	 Start	
Universal	 SYBR	Green	Master	Mix	 (Roche,	 Cat.	No.	 04	913	850	001).	 20	ng	of	 cDNA	were	
used	per	well.	 The	 primers	 used	 are	 listed	 in	 Figure	 4B	 and	were	 designed	 for	 the	 specie	
gallus	gallus.	All	reactions	were	performed	using	the	same	conditions:	50	°C	for	2	min,	95	°C	
for	10	min;	40	cycles	at:	95	°C	for	15	s,	60	°C	for	1	min.	The	experiment	was	repeated	3	times	









was	 immediately	 transferred	 to	 80	 °C	 for	 storage.	 For	 the	 DRG	 samples	 the	 same	
experimental	 groups	 and	 culture	 conditions	 as	 for	 the	 qRT-PCR	 experiment	were	 applied.	
After	 48	 h	 of	 incubation	 in	 the	 respective	 conditioned	 medium,	 the	 DRG-explants	 were	
subjected	to	the	same	treatment	as	described	above	for	ASC,	except	of	centrifugation	which	
was	performed	at	900	rpm.	A	protein	yield	of	at	least	100	μg	per	experimental	condition	was	
required	 for	 phosphoproteomics.	 The	 experiments	 were	 repeated	 3	 times,	 resulting	 in	 3	
independent	samples	for	ASC	and	DRG-explants.	
Cells	 were	 lysed	 in	 8M	 Urea	 (Sigma),	 0.1M	 ammonium	 bicarbonate	 in	 the	 presence	 of	




37	 °C	 and	 alkylated	with	 10	mM	 chloroacetamide	 for	 30	min	 at	 37	 °C.	 After	 diluting	 the	
samples	with	100	mM	ammonium	bicarbonate	buffer	to	a	final	urea	concentration	of	1.6	M,	
the	 proteins	 were	 digested	 by	 incubation	 with	 sequencing-grade	 modified	 trypsin	 (1/50,	
w/w;	Promega,	Madison,	Wisconsin)	overnight	at	37	°C.	After	acidification	using	5%	TFA,	the	
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peptides	 were	 desalted	 on	 C18	 reversed-phase	 spin	 columns	 according	 to	 the	
manufacturer’s	instructions	(Macrospin,	Harvard	Apparatus)	and	dried	under	vacuum.	
Peptide	 samples	 were	 enriched	 for	 phosphorylated	 peptides	 using	 Fe(III)-IMAC	
cartridges	 on	 an	 AssayMAP	 Bravo	 platform	 as	 recently	 described	 (PMID:	 28107008).	 The	





formic	 acid)	 and	 5%	 solvent	 B	 (80%	 acetonitrile,	 19.9%	 water,	 0.1%	 formic	 acid)	 to	 30%	
solvent	 B	 over	 90	minutes	 at	 a	 flow	 rate	 of	 200	 nl/min.	Mass	 spectrometry	 analysis	 was	
performed	 on	 a	 Tribrid	 Orbitrap	 Lumos	 mass	 spectrometer	 equipped	 with	 a	
nanoelectrospray	ion	source	(both	Thermo	Fisher	Scientific).	Each	MS1	scan	was	followed	by	
high-collision-dissociation	 (HCD)	 of	 the	 10	 most	 abundant	 precursor	 ions	 with	 dynamic	
exclusion	for	30	seconds.	The	total	cycle	time	was	approximately	1	s.	For	MS1,	1e6	ions	were	
accumulated	 in	 the	 Orbitrap	 cell	 over	 a	 maximum	 time	 of	 100	 ms	 and	 scanned	 at	 a	
resolution	of	120,000	FWHM	(at	200	m/z).	MS2	scans	were	acquired	at	a	 target	setting	of	
100%,	accumulation	 time	of	54	ms	and	a	 resolution	of	30,000	FWHM	(at	200	m/z).	 Singly	
charged	 ions	 and	 ions	 with	 unassigned	 charge	 state	 were	 excluded	 from	 triggering	 MS2	
events.	The	normalized	collision	energy	was	set	to	30%,	the	mass	isolation	window	was	set	
to	1.4	m/z	and	one	microscan	was	acquired	for	each	spectrum.	
The	 acquired	 raw-files	 were	 imported	 into	 the	 Progenesis	 QI	 software	 (v2.0,	
Nonlinear	 Dynamics	 Limited),	which	was	 used	 to	 extract	 peptide	 precursor	 ion	 intensities	
across	all	samples	applying	the	default	parameters.	The	generated	mgf-files	were	searched	
against	a	human/chicken	database	containing	usually	observed	contaminants	and	a	total	of	
41592	 (human,	 download	 date	 2019/03/07	 from	 www.uniprot.org)/55856	 (chicken,	
download	 date	 2020/04/14	 from	www.uniprot.org)	 protein	 sequences	 using	MASCOT	 and	
the	 following	 search	 criteria:	 full	 tryptic	 specificity	 was	 required	 (cleavage	 after	 lysine	 or	





discovery	 rate	 (FDR)	 to	 1%	 on	 the	 peptide	 and	 protein	 level,	 respectively,	 based	 on	 the	
number	 of	 reverse	 protein	 sequence	 hits	 in	 the	 datasets.	 The	 relative	 quantitative	 data	
obtained	 were	 normalized	 and	 statistically	 analyzed	 using	 our	 in-house	 script	 as	 above	





The	 mass	 spectrometry	 proteomics	 data	 have	 been	 deposited	 to	 the	 ProteomeXchange	




Data	 were	 analyzed	 by	 one-way	 analysis	 of	 variance	 (ANOVA)	 following	 Bonferroni	





The	 phenotype	 of	 ASC	 was	 quantitatively	 characterized	 using	 representative	 images	 and	







As	 illustrated	 in	 Figure	 1,	 various	 NTF	 were	 used	 for	 stimulation	 of	 axonal	 growth.	
Interestingly,	all	the	growth	factors	promoted	considerable	axonal	outgrowth	in	comparison	
to	 GM.	 Notably,	 NT3	 promoted	 significant	 axonal	 outgrowth	 (Figure	 2A-C).	 Quantitative	
measurements	 of	 axonal	 length	 (in	 μm)	 from	 DRG-explants	 treated	 with	 growth	 factors	
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resulted	in	413	±	182	for	NGF,	405	±	116	for	GDNF,	419	±	73	for	BDNF,	352	±	74	for	CNTF,	
463	±	121	 for	NT3,	291	±	51	 for	NT4	and	282	±	41	 for	GM	 (Table	1).	 Interestingly,	 axonal	
growth	 pattern	 in	 response	 to	 various	 NTF	 treatments	 appeared	 to	 be	 distinctive.	 NGF	
promoted	 dense	 axonal	 growth	 without	 longer	 projections	 in	 contrast	 to	 GDNF,	 which	











































































Figure 2. Distinct effects of individual NTF on axonal outgrowth. (A) Microphotographs of dorsal root ganglion (DRG) explants treated with
NTF or growth medium alone (GM), (B) Quantitative measurements of axonal length (μm), and (C) Measurements of axonal area (mm2).
The scale bar represents 500 μm. The bars represent mean ± SD of n = 12. Significant differences are indicated as * p < 0.05, ** p < 0.01






in	 comparison	 to	unstimulated	ASC	and	NTF	 treatment	alone	 (Figure	3A	 -	C).	Quantitative	
measurements	of	axonal	length	(in	μm)	amounted	to	526	±	87	for	CM-NGF-ASC,	505	±	75	for	
CM-GDNF-ASC,	598	±	118	for	CM-BDNF-ASC,	599	±	58	for	CM-CNTF-ASC,	765	±	134	for	CM-
NT3-ASC,	 522	 ±	 80	 for	 CM-NT4-ASC	 and	 469	 ±	 99	 for	 CM-ASC	 (Table	 1).	 Significant	
differences	 were	 observed	 for	 CM-BDNF-ASC	 (p<0.05),	 CM-CNTF-ASC	 (p<0.001),	 CM-NT3-
ASC	 (p<0.001)	 and	CM-NT4-ASC	 (p<0.001).	 Particularly,	 CM-NT3-ASC	 triggered	 significantly	




(Table	 1).	 In	 agreement	 with	 the	 axonal	 length	 measurements,	 CM-NT3-ASC	 exhibited	
significantly	 higher	 axonal	 outgrowth	 area	 (Figure	 3C).	 Notably,	 CM-NT3-ASC	 promoted	






























Analysis	by	qRT-PCR	 for	 relative	STAT-3	RNA	 levels	 resulted	 in	Ct	values	of	1.65	±	0.57	 for	
CM-NT3-ASC,	0.42	±	0.14	for	CM-ASC,	0.79	±	0.17	for	NT3	and	0.63	±	0.14	for	GM	(Figure	4C).	
Relative	GAP-43	Ct	RNA	values	showed	3.37	±	1.10	for	CM-NT3-ASC,	0.52	±	0.23	for	CM-ASC,	







mass	 spectrometry-based	 phosphoproteomic	 analysis	 was	 performed.	 Two	 different	
experiments	were	carried	out	 comparing	NT3-ASC	vs.	ASC	as	well	 as	DRG-explant	 cultures	
treated	 with	 various	 stimuli	 conditions,	 i.e.,	 CM-NT3-ASC,	 CM-ASC,	 NT3,	 and	 GM.	 All	
quantitative	 analyses	 were	 performed	 in	 biological	 triplicates	 analyzing	 phosphopeptide-
enriched	samples	using	a	label-free	quantification	of	LC-MS	approach	(PMID:	30867597).	In	
total,	 10352	 and	 7440	 phosphorylation	 sites	 were	 quantified	 for	 ASC	 and	 DRG-explants,	
respectively	 (Figure	 5,	 Figures	 S3	 and	 S4,	 and	 Tables	 S1	 and	 S2).	 ASC	 in	 response	 to	 NT3	
stimulation	 exhibited	 21	 significantly	 changing	 phosphorylation	 sites	 (Figure	 5A).	 These	
include	FRMD8	and	NOTCH2	which	are	involved	in	the	regulated	growth	factors	release	and	
neural	progenitor	cell	(NPC)	maintenance	and	differentiation	[168–170].	Enrichment	analysis	
of	 the	altered	phosphorylation	 sites	 further	 showed	 that	 the	notch	 signaling	pathway	and	
the	active	domain	of	notch2	were	significantly	affected	by	 the	NT3-stimulation	 (Figure	5B,	
Figure	S3,	and	Table	S1).	
Subsequent	 comparison	 of	 DRG-explants	 treated	 with	 CM-NT3-ASC	 vs.	 GM	 displayed	 10	
significantly	 changing	 phosphorylation	 sites	 (Figure	 5C	 and	 D,	 Figures	 S3	 and	 Table	 S2).	
Proteins	associated	with	these	sites	include	TBCEL,	EVL,	SPEN	and	MAP1A	which	are	linked	
to	growth	cone	formation	and	the	polymerization,	reorganization	and	stabilization	of	axonal	
cytoskeletal	 proteins	 (i.e.,	 tubulin	 and	 actin)	 [171–178].	 	 An	 enrichment	 analysis	 further	
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were	 observed	 upon	 CM-NT3-ASC	whereas	 treatment	with	 NT3	 alone	 or	 CM-ASC	 did	 not	
have	a	significant	impact	on	the	p-value	frequency	distribution	(Figure	S3A	–	C	and	Figure	S4),	
indicating	 that	 the	CM	of	NT3-stimulated	ASC	 is	 the	 trigger	 for	 the	phosphorylation-based	




Functional	 nerve	 regeneration	 is	 clinically	 challenging	 [45].	 After	 injury,	 affected	 neurons	
and	 glial	 cells	 require	 neurotrophic	 support	 and	 structural	 guidance	 for	 survival	 and	
regeneration	[72].	Peripheral	nervous	system	is	capable	of	spontaneous	regeneration	due	to	
the	 intrinsic	 regenerative	 capacity.	 However,	 gap	 injuries	 and	 chronic	 nerve	 injuries,	 in	
particular,	 require	exogenous	 trophic	and	 topographical	 support	 for	effective	 regeneration	
[2,179].	 Nerve	 tissue	 engineering	 holds	 promise	 for	 developing	 a	 viable	 new	 strategy	
subjective	to	the	availability	of	effective	neurotrophic	cell	sources	[180].	MSC	derived	from	
variety	 of	 tissues	 have	 been	 widely	 known	 to	 possess	 multilineage	 capacity	 and	
multifunctional	potency	[100,155,158,180].	The	ability	of	these	cells	to	support	the	trophic	
needs	 of	 the	 neuronal	 cells	 for	 survival,	 development,	 and	 plasticity	 can	 be	 defined	 as	
“neurotrophic	capacity”	within	the	context	of	functional	multipotency	of	the	stem	cells.	ASC	
release	 a	 variety	 of	 neurotrophins	 and	 support	 neuronal	 survival	 and	 axonal	 outgrowth,	
suggesting	their	neurotrophic	activity	 [100,180].	Furthermore,	several	studies	reported	the	
potential	of	ASC	for	supporting	the	neuronal	survival	and	axonal	regeneration	by	releasing	a	




The	 neurotrophic	 potential	 of	 ASC	 lies	 within	 the	 secretome	 containing	 a	 variety	 of	
biochemical	 and	 molecular	 factors	 [8,109,154,155,162].	 ASC	 exosomes	 with	 miRNA21,	
miRNA222,	and	miRNAlet7a	support	neuronal	survival	by	 inhibiting	apoptotic	pathways.	 In	
addition,	 the	 secretome	 of	 ASC	 contains	wide	 range	 of	 growth	 factors,	 i.e.,	 nerve	 growth	
factor	(NGF),	glial	cell-derived	neurotrophic	factor	(GDNF),	brain-derived	neurotrophic	factor	
(BDNF),	 neurotrophin-3	 (NT3),	 insulin-like	 growth	 factor	 1	 (IGF-1),	 vascular	 endothelial	
growth	factor	(VEGF),	epidermal	growth	factor	(EGF),	basic	fibroblast	growth	factor	(bFGF),	





the	 neurotrophic	 capacity	 of	 ASC	 following	 exogenous	 NTF	 stimulation.	 For	 this,	 we	 have	
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primarily	evaluated	NTFs	representing	three	different	families,	i.e.,	the	neurotrophins	(NGF,	
BDNF,	NT3,	 and	NT4),	 the	GDNF	 family	of	 ligands	 (GDNF),	 and	 the	neurotrophic	 cytokines	
(CNTF),	 for	 ex	 vivo	 stimulation	 of	 ASC.	 The	 resulting	 condition	 medium	 (CM)	 as	 well	 as	
individual	NTFs	were	investigated	separately	for	their	capacity	to	promote	axonal	outgrowth	
using	DRG	explants	in	vitro.	
The	 cellular	 and	molecular	biology	of	 the	different	 species	 are	highly	 conserved	 [181,182]		




such	 as	 easy	 accessibility,	 handling,	 modest	 costs,	 and	 three-dimensional	 cellular	 contact	
between	neuronal	and	non-neuronal	cells.	Although	the	 injury-induced	changes	are	 largely	
common	among	various	stages	of	the	neurons,	embryonic	neurons	possess	higher	plasticity	
than	 the	 adult	 neurons	 [74,158,163,164,179].	 However,	 several	 studies	 have	 shown	 that	
injury-induced	 expression	 of	 various	 growth	 factors	 and	 surface	 receptors	 that	 are	




consider	 the	compatibility	of	 the	 study	design	with	 the	associated	principles	of	 concerned	
disciplines,	 i.e.,	 stem	 cell	 biology,	 neurobiology,	 pharmacology,	 and	 toxicology.	 For	 this,	
there	 were	 set	 of	 guidelines,	 i.e.,	 non-clinical	 safety	 evaluation	 of	 drug	 and	 biologic	
combinations	 published	 by	 European	 Medical	 Agency	 (EMA)	 as	 well	 as	 food	 and	 drug	
administration	 (FDA)	 [185].	 In	 compliance	 with	 the	 above-indicated	 guidelines,	 our	
multimodal	system	represents	a	valuable	in	vitro	model	for	basic	and	translational	studies.	
NGF	 is	 a	 well-studied	 neurotrophic	 factor	 due	 to	 its	 role	 in	 neuronal	 survival	 and	
axonal	 regeneration.	 In	 our	 assay,	 NGF	 clearly	 elicited	 abundant	 axonal	 outgrowth	 with	
strong	branching,	as	reported	earlier	[74].	This	effect	is	caused	by	NGF’s	specific	binding	to	
the	high-affinity	TrkA	receptor	of	sensory	and	sympathetic	neurons	[186].	GDNF,	through	its	
binding	 to	 the	 high-affinity	 GFRα	 complex	 [147],	 promoted	 relatively	 longer	 axonal	
projections	 in	 contrast	 to	NGF.	GDNF	has	 been	proven	 to	 exert	 trophic	 effects	 on	 injured	
motor	 and	 sensory	 axons	 [77].	 This	 observation	 is	 supported	 by	 its	 upregulation	 in	 the	
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ventral	 and	 dorsal	 root	 following	 injury	 [187].	 The	 diverse	 functions	 of	 BDNF	 are	 mainly	
mediated	by	 the	TrkB	 receptor	 [23],	and	 it	was	 found	 to	be	especially	elevated	 in	 sensory	




loss	 [75,193].	NT3	exerts	 its	action	by	binding	 to	 the	high-affinity	 receptor	TrkC.	CNTF	and	
NT4	showed	minimal	enhancement	of	axonal	outgrowth	in	terms	of	axonal	length	as	well	as	







potency	of	ASC	 for	promoting	axonal	 regeneration.	 In	particular,	NT3-stimulated	ASC	 (CM-
NT3-ASC)	in	comparison	to	all	other	NTF,	elicited	robust	axonal	outgrowth.	When	compared	
to	NGF,	 it	 becomes	 evident	 that	 the	 increased	 axonal	 area	 did	 not	mainly	 originate	 from	
axonal	 branching,	 since	 NT3-induced	 axonal	 projections	 are	 linearly	 aligned	 and	 well	
organized,	 but	 most	 probably	 from	 increased	 neuronal	 survival.	 The	 role	 of	 NT3	 in	
preventing	neuronal	loss	following	injury	has	been	well	documented	[75,193,197,198].	ASC	
have	 been	 shown	 to	 express	 receptors	 for	 various	 NTF	 [101,103,160–162].	 Thus,	 the	
exogenous	NTF	stimuli	may	amplify	the	neurotrophic	capacity	of	ASC	through	their	receptor	
binding,	 leading	 to	 enhanced	 expression	 of	 regeneration-associated	molecules,	 cytokines,	
and	growth	factors.	Interestingly,	a	phosphoproteomic	analysis	revealed	significant	changes	
taking	place	in	the	phosphorylation	of	different	proteins	involved	in	growth	factor	signaling,	
cytokine	 release,	 stem	 cell	 population	 maintenance,	 and	 differentiation.	 In	 particular,	
FRMD8	and	Notch2	showed	significantly	enhanced	phosphorylation	 in	NT3-stimulated	ASC	
in	comparison	to	unstimulated	ASC.	
FRMD8	 mediates	 the	 controlled	 release	 of	 growth	 factors	 and	 cytokines	 from	 cells	 by	
regulating	the	active	complex	of	ADAM17	and	iRhom	[170].	Lack	of	FRMD8	activity	leads	to	
degradation	 of	 ADAM17	 and	 iRhom,	 resulting	 in	 low	 or	 no	 release	 of	 the	 growth	 factors	
	 63	
[170].	 Several	 growth	 factors,	 i.e.,	 EGF	 receptor	 ligand	 amphiregulin	 (AREG),	 transforming	
growth	factors	alpha	(TGFα),	heparin-binding	EGF,	epigen,	and	epiregulin,	are	regulated	by	
the	 coordinated	 function	 of	 these	 molecules	 [199,200].	 Within	 this	 context,	 elevated	
phosphorylation	 of	 FRMD8	 in	 the	 NT3-stimulated	 ASC	 gains	 significance	 and	 shows	 the	
possibility	 of	 the	 increased	 release	 of	 growth	 factors	 and	 cytokines.	 Therefore,	 a	 detailed	
analysis	of	 the	composition	of	 the	resulting	secretome	may	provide	more	 insights	 into	the	
topic.	
Notch2	 plays	 a	 key	 role	 in	 the	 maintenance	 of	 neural	 progenitor	 cells	 (NPC)	 and	
differentiation	[168].	Several	studies	reported	that	the	mere	activation	of	notch2	is	sufficient	
for	 the	maintenance	and	proliferation	of	 the	NPC	 [201,202].	On	 the	other	hand,	 a	 lack	of	
Notch2	expression	leads	to	differentiation	of	NPC	into	the	neuronal	phenotype	[168].	These	
observations	 suggest	 that	 NT3-stimulated	 ASC	 might	 have	 attained	 endogenous	 changes	
toward	 neuronal	 lineage,	 but	 not	 complete	 differentiation.	 These	 findings	 are	 further	
strengthened	 by	 microscopic	 evidence	 showing	 the	 NT3-stimulated	 ASCs’	 transition	 into	
S100	positive	phenotype	within	3	days,	although	these	cells	did	not	yet	express	other	typical	
glial	markers	 such	 as	GFAP	 and	p75.	 Furthermore,	DRG	explant	 treated	with	CM-NT3-ASC	




EVL	 regulates	 actin	 filament	 polymerization	 and	 controls	 a	 range	 of	 processes	 that	 are	
dependent	on	the	actin	cytoskeleton	remodeling,	e.g.,	axonal	growth	and	extension	[99].	An	
actin-filled	growth	cone	precisely	navigates	axonal	elongation,	 involving	a	dynamic	process	





to	 differential	 guidance	 cues.	 On	 the	 other	 hand,	 MAP1A	 is	 a	 major	 component	 of	 the	
microtubule-linked	 fibrillar	 matrix	 of	 axons	 [175],	 regulating	 the	 microtubule	 cytoskeletal	








CM	 derived	 from	 NTF-stimulated	 ASC,	 a	 transcriptional	 analysis	 of	 the	 regeneration-
associated	 genes	 (RAG)	 STAT-3	 and	 GAP-43	 was	 performed	 using	 qRT-PCR.	 For	 this,	 DRG	
explants	 treated	 with	 the	 most	 promising	 treatment	 condition,	 i.e.,	 CM-NT3-ASC,	 were	
processed.	 The	 resulting	 data	 revealed	 a	 significant	 upregulation	 of	 RAGs.	 GAP-43	 is	
upregulated	 in	 the	 perikaryon	 of	 neuronal	 cells	 after	 axotomy-induced	 inflammatory	
environment,	calcium	influx,	and	retrograde	signaling	of	neurotrophic	factors	[9,22,26].	GAP-
43	participates	in	the	formation	of	the	axonal	growth	cone	and	its	associated	lamellipodiae	
and	 filopodiae	 for	 axon	 elongation	 and	 path	 finding	 [7,23].	 GAP-43	 is	 also	 upregulated	 in	
denervated	SC,	where	it	supports	their	survival	and	maintenance	[9,203,204].	Furthermore,	
GAP-43	 is	 involved	 in	supporting	the	 long-term	survival	of	denervated	SC,	as	well	as	 in	the	
maintenance	of	the	phenotype	of	repair	SC	[152].	JAK/STAT3,	on	the	other	hand,	belongs	to	
the	 main	 transcriptional	 mediators	 that	 encode	 for	 the	 expression	 of	 growth-associated	
genes	such	as	GAP-43	[9,19,152].	Its	transcription	is	activated	by	receptor-ligand	binding	and	







require	 molecular,	 trophic,	 and	 guidance	 support	 for	 effective	 regeneration.	 Although	
peripheral	 nervous	 system	 is	 capable	 of	 spontaneous	 regeneration	 due	 to	 the	 intrinsic	
regenerative	capacity,	 long-gap	and	chronic	nerve	injuries,	 in	particular,	require	exogenous	
bioactives	 support	 for	 regeneration	 [72].	 Clinically	 optimal	 nerve	 regeneration	 can	 be	
achieved	 by	 orchestrating	 a	 permissive	 microenvironment	 at	 the	 injury	 site.	 For	 this,	
complex	 array	 of	 biological	 factors	 is	 required	 [72,156].	 Up-to-date,	 autologous	 nerve	
grafting	 remains	 the	 gold	 standard	 treatment	 for	 nerve	 gap	 injuries,	 which	 might	 be	
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attributed	 to	 the	 presence	 of	 Schwann	 cells	 and	 structural	 extracellular	 matrix	 proteins	
[25,45].	 For	 the	 future,	 nerve	 conduits	 combined	with	 a	 cell-based	 therapy	might	 be	 the	
most	natural	and	effective	way	to	mimic	 the	autograft’s	 features	 [206].	Neurotrophic	cells	
provide	 long-term	 availability	 of	 NTF	 in	 a	 physiological	 context,	 which	 includes	 adequate	
release	 kinetics	 and	 quantities,	 and	 feedback	 mechanisms	 regulating	 NTF	 release	 [24].	
Moreover,	 transplanted	 stem	 cells	 create	 an	 interactive	 regenerative	 niche,	 not	 only	 by	
secreting	 factors	 but	 also	 by	 responding	 to	 endogenous	 signals.	 Although	 the	 results	 are	
promising,	 existing	 strategies	 for	 improving	 the	 trophic	 capacity	 of	 ASC,	 i.e.,	 biochemical	
induction	[86,102]	or	genetic	induction	[75,207,208],	are	associated	with	several	drawbacks	
such	as	lengthy	processes	(more	than	three	weeks),	safety	and	regulatory	hurdles.	Moreover,	
several	 studies	 reported	the	deleterious	effects	of	using	 large	number	of	biological	 factors	
for	 axonal	 outgrowth	 in	 vivo	 [157].	 Thus,	 there	 is	 need	 for	 simple	 yet	 effective	 strategies	
such	as	cell	with	improved	trophic	capacity	that	is	similar	to	SC.	
We,	therefore,	propose	in	the	present	study	a	simple	and	effective	strategy	involving	ex	vivo	
stimulation	 of	 ASC	 using	 exogenous	NTF.	Notably,	 our	 approach	may	 reduce	 or	 avoid	 the	
complexity	of	administering	additional	exogenous	growth	factors	 in	vivo,	while	maximizing	
the	 regenerative	 support	 for	 severed	 neuro-glial	 cells.	 Among	 all	 the	 NTF,	 NT3	 exerted	 a	
remarkable	 stimulus	 to	 enhance	 the	 neurotrophic	 capacity	 of	 ASC,	 as	 evidenced	 by	 the	
phenotypic	 transition,	axonal	outgrowth,	 transcriptional,	and	phosphoproteomic	data.	NT3	
quantitative	measurements	 resulting	 from	CM	of	 different	 experiments	 together	with	 the	
axonal	 outgrowth	 outcome	 indicate	 that	 ASC’s	 enhanced	 neurotrophic	 capacity	 for	
triggering	 axonal	 growth	 in	 vitro	 is	 NT3	 dependent.	 Although	 the	 underlying	 mechanism	
remains	to	be	elusive,	several	 lines	of	evidence	at	cellular	and	molecular	 level	support	the	




but	 not	 the	 axons,	 as	 evidenced	 by	 the	 NT3	 heterozygous	 knockout	 mice	 displaying	 the	
decreased	 SCs,	 myelin	 retardation	 and	 high	 neuro-filament	 packing	 density	 of	 axons	






peripheral	 nerve	 injury	 [209].	 However,	 chronic	 nerve	 injuries	 result	 in	 SC	 atrophy	 and	
reduced	expression	of	receptors	and	growth	factors	by	SC	[210,211].	Given	these	facts,	NT3	
cross-talk	with	DRG	neurons	appears	to	be	one-way.	
Thus,	 the	 data	 and	 knowledge	 obtained	 in	 the	 present	 study	 forms	 strong	 basis	 for	 the	
further	refinement	of	the	therapeutic	strategy	and	evaluation	in	animals	(immune-deficient	




In	 the	 present	 study,	 we	 demonstrated	 the	 feasibility	 of	 modulating	 ASC’s	 neurotrophic	
potential	in	vitro	as	evidenced	by	axonal	outgrowth,	transcriptional,	and	phosphoproteomic	
data.	 In	 particular,	 the	 conditioned	 medium	 resulting	 from	 NT3-stimulated	 ASC	 triggered	
robust	axonal	outgrowth	with	significantly	 longer	projections.	Together,	these	findings	and	
observations	 provide	 new	 knowledge	 that	 should	 be	 relevant	 to	 ASC	 biology,	 basic	
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Introduction:	 Digital	 nerves	 are	 among	 the	most	 frequently	 repaired	 peripheral	 nerves	 at	
hand	 surgery	 units	 worldwide.	 Even	 though	 standard	 treatment	 methods	 are	 well	
established,	they	are	associated	with	several	undeniable	disadvantages	that	may	have	long-
lasting	 impacts	 on	 the	 patients’	 quality	 of	 life.	 Thus,	 the	 aim	of	 the	 present	 study	was	 to	
investigate	alternative	treatment	strategies	involving	fibrin	gel	for	digital	nerve	injuries	with	
no	 gap	 or	 a	 nerve	 gap-defect.	Methods:	 In	 study	 1,	 patients	 with	 non-gap	 digital	 nerve	








by	 electroneurography,	 were	 acquired.	 Results:	 36	 patients	 with	 46	 nerve	 injuries	 were	
included	 in	 the	 study,	with	 a	mean	 age	 of	 36	±	14	 years.	 No	 adverse	 events	 occurred.	 In	
study	1,	group	1b	experienced	enhanced	sensory	recovery	and	higher	patient	satisfaction	in	
the	phase	of	early	nerve	regeneration	compared	to	group	1a.	In	study	2,	group	2b	showed	




were	 derived	 from	 all	 nerve	 injuries	 analyzed.	 Conclusion:	 Enhancement	 of	 early	 nerve	
regeneration	 by	 experimental	 treatment	 with	 fibrin	 sealant	 and	 fibrin	 conduit	 can	 be	
assumed,	but	would	need	to	be	confirmed	by	a	larger	patient	population.	The	final	outcome	








rising,	 and	 the	majority	 of	 injuries	 affect	 digital	 nerves	 [212,213].	 Like	 all	 upper	 extremity	
nerve	 injuries,	 nerve	 injuries	 of	 wrist	 and	 hand	 are	 mainly	 caused	 by	 domestic	 or	 work-
related	accidents	[4,5],	and	typically	affect	male	and	younger	individuals	(mean	age	around	
30	years)	[4–6].		Despite	advances	in	microsurgical	techniques,	the	functional	outcome	often	
remains	 suboptimal	 after	 the	 reconstruction	 due	 to	 reduced	 sensation,	 impaired	 motor	




means	 of	 tension-free	 end-to-end	 coaptation	 using	 epineural	 suturing	 [30,214].	 Primary	
repair	and	accurate	coaptation	of	nerve	endings	with	fascicular	alignment	and	blood	vessel	
continuity	 are	 likely	 to	 result	 in	 better	 outcomes	 and	 fewer	 complications	 for	 the	 patient	
[1,16].	 However,	 epineural	 sutures	 generate	 inflammatory	 responses,	which	may	 result	 in	
increased	 fibrosis	 and	 thus	 inhibited	 axonal	 regeneration	 [31].	 Thus,	 the	 concept	 of	
sutureless	 nerve	 repair	 has	 been	 studied	 [31].	 Several	 studies	 investigated	 outcome	 and	
stability	 of	 nerve	 coaptations	 with	 the	 help	 of	 fibrin	 gel	 [32,33].	 Reported	 results	 are	
conflicting.	 Some	 authors	 stated	 equivalent	 reliability	 and	 even	 superior	 outcomes	 of	
sutureless	 coaptions	 compared	 to	 epineural	 repair	 [34–36].	 The	 advantages	 are	 obviously	
decreased	 inflammation	 and	 scar	 tissue	 formation.	 However,	 other	 authors	 reported	 on	
insufficient	 stability	 provided	 by	 the	 fibrin	 gel,	 which	 may	 lead	 to	 gapping	 or	 even	
disconnection	 of	 the	 nerve	 ends	 [37,38].	 A	 valid	 compromise	 might	 be	 to	 perform	 a	
minimum	 of	 epineural	 sutures	 with	 stabilization	 of	 the	 suture	 site	 by	 fibrin	 gel.	 This	
technique	resulted	in	increased	tensile	strength	[39,40]	and	has	been	applied	successfully	in	
vivo	[34,41],	despite	concerns	that	fibrin	might	impede	the	axonal	regeneration	[42].		
In	 case	 of	 longer	 nerve	 defects,	 the	 nerve	 segments	 proximal	 and	 distal	 to	 the	
neurorrhaphy	 can	 usually	 not	 be	 sufficiently	 mobilized	 in	 order	 to	 perform	 a	 tensionless	
surgical	repair	at	the	site	of	injury	[43].	Therefore,	digital	nerve	gaps	greater	than	5	mm	are	
commonly	 bridged	 with	 autologous	 nerve	 grafts	 taken	 from	 the	 patient’s	 forearm	 or	 leg	
[44,45].	The	nerve	autograft	provides	a	favorable	environment	for	the	outsprouting	axons:	
an	 intact	 extracellular	 matrix	 for	 guidance	 and	 a	 population	 of	 residing	 Schwann	 cell	
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providing	neurotrophic	 factors	and	adhesion	molecules	 [1].	Nevertheless,	 the	sacrifice	of	a	
healthy	nerve	 is	required,	which	not	only	creates	a	second	surgery	site,	but	also	bears	the	
risk	 of	 sensitivity	 loss,	 pain,	 and	 suboptimal	 scarring	 at	 the	 donor	 site.	 Furthermore,	
challenges	are	present	at	 the	recipient	site	as	well,	 such	as	nerve	size	and	type	mismatch,	
neuroma	 formation,	 hypersensitivity,	 and	 only	 partial	 recovery	 of	 motor	 function	 [1,45].	
Consequently,	 suitable	 non-autologous	 bridging	 options	 were	 researched,	 aiming	 at	
providing	 a	 growth	 supporting	 intraluminal	 microenvironment,	 and	 preventing	 aberrant	
axonal	 outgrowth	 and	 false	 reinnervation	 [47].	 One	 promising	 alternative	 to	 autografts	 is	
currently	seen	 in	processed	nerve	allografts	 [44,54,215].	With	 the	help	of	decellularization	
processes,	 any	 human	 leukocyte	 antigen	 (HLA)-target	 tissue	 is	 removed	 in	 order	 to	 avoid	
graft	 rejection	 and	 the	 need	 for	 immunosuppression	 of	 the	 patient	 [216].	 Yet,	 the	major	
challenge	faced	by	allografts	are	ongoing	 improvements	of	these	complex	decellularization	
procedures	 [216].	 Nerve	 conduits	 represent	 another	 intensively	 investigated	 treatment	
option.	 Nowadays,	 conduits	 used	 to	 guide	 and	 support	 outsprouting	 axons	 are	 made	 of	
biodegradable	polymers,	which	can	be	produced	from	a	large	variety	of	synthetic	or	natural	






such	 as	 1)	 easy	 handling	 and	 adaptability,	 2)	 biocompatibility,	 3)	 flexible	 consistency	with	




as	 a	 hemostat,	 a	 sealant	 and	 an	 adhesive	 is	 FDA-approved	 [58–60].	 Fibrin	 gel	 can	 be	
prepared	 autologously	 from	 individual	 donors,	 and	 it	 is	 also	 commercially	 available	 from	
different	companies	[32,58].	It	has	proven	excellent	biocompatibility	in	both	cases	[53,58,61].	
Fibrin	 gel	 generally	 consists	 of	 two	 components:	 thrombin	 with	 calcium	 chloride,	 and	
fibrinogen	with	or	without	 factor	 XIII	 and	 fibronectin,	 in	 some	 cases	 stabilized	by	 an	 anti-
fibrinolytic	 agent	 like	 aprotinin	 [61–63].	 In	 order	 to	 adapt	 to	 its	 field	 of	 application,	 the	
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dissolving,	 coagulation,	 malleability	 and	 permeability	 characteristics	 of	 fibrin	 gel	 can	 be	
adapted	 by	 modifying	 the	 concentrations	 of	 its	 components	 accordingly	 [62,65,226].	 	 A	









been	 translated	 into	 humans.	 Therefore,	 this	 prospective,	 randomized	 two-arm	pilot	 non-
inferiority	study	was	conducted	in	order	to	assess	and	compare	the	outcomes	observed	after	
experimental	 versus	 standard	 treatment	 of	 peripheral	 nerve	 injuries,	 either	 with	 no	 gap	
(study	1)	or	with	a	critical	sized	(>	5mm)	defect	(study	2).	In	study	1,	the	standard	treatment	
comprised	 epineural	 sutures	 (group	 1a),	 while	 the	 experimental	 treatment	 included	
additional	 fibrin	 sealant	around	 the	epineural	 sutures	 (group	1b).	 In	 study	2,	 the	 standard	
treatment	involved	an	autograft	(group	2a),	while	the	experimental	treatment	used	a	fibrin	
nerve	 conduit	 (group	 2b)	 to	 bridge	 the	 gap.	 We	 hypothesized	 non-inferiority	 for	 the	
experimental	 treatment	 options	 in	 terms	 of	 clinical	 outcome	 and	 patient	 satisfaction	
compared	to	the	respective	standard	treatment.	Validation	of	the	experimental	treatments	
for	 clinical	 use	 would	 allow	 optimized	 procedures	 of	 peripheral	 nerve	 repair	 in	 terms	 of	





This	 single-center	 two-arm-controlled	 pilot	 non-inferiority	 study	 was	 performed	 at	 the	
Department	 of	 Plastic,	 Reconstructive,	 Aesthetic	 Surgery,	 and	 Hand	 Surgery,	 at	 the	
University	Hospital	Basel.	The	study	was	in	accordance	with	the	principles	announced	in	the	
Declaration	 of	 Helsinki,	 the	 guidelines	 of	 Good	 Clinical	 Practice	 (GCP)	 issued	 by	 the	
International	 Conference	 on	 Harmonisation	 of	 Technical	 Requirements	 for	 Registration	 of	
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Pharmaceuticals	 for	Human	Use	 (ICH),	 and	 Swiss	 regulatory	 authority’s	 requirements.	 The	
study	protocol	was	approved	by	the	local	ethics	committee	(Ref.Nr.	EK:	241/12).		
Patients	aged	between	18	and	90	years	at	 the	 time	of	 the	surgery	with	a	 traumatic	nerve	
injury	 of	 one	 or	 multiple	 finger(s)	 that	 was	 considered	 for	 peripheral	 nerve	 repair,	 were	
considered	 to	 be	 eligible	 for	 the	 study.	 Patients	with	 known	 hypersensitivity	 or	 allergy	 to	
fibrin	 were	 excluded.	 After	 measuring	 the	 nerve	 gap	 during	 surgery,	 randomization	
envelopes	were	drawn	either	for	study	1	or	study	2,	depending	on	the	size	of	the	nerve	gap.	
In	 study	 1,	 nerve	 repair	 for	 nerve	 defects	 <	 5mm	 was	 performed.	 Patients	 were	 either	
randomized	 to	 group	 1a	 (standard)	 and	 treated	 with	 epineural	 suture,	 or	 to	 group	 1b	
(experimental)	 and	 treated	with	epineural	 suture	 and	additional	 fibrin	 sealant.	 In	 study	2,	
nerve	 repair	 for	 critical	 sized	 (>	 5mm)	 defects	 was	 performed.	 Patients	 were	 either	
randomized	to	group	2a	(standard)	and	treated	with	autologous	nerve	transplantation	from	
the	lateral	antebrachial	cutaneous	nerve	(LACN)	or	to	group	2b	(experimental)	and	treated	
with	a	FNC.	 In	 cases	where	 several	 fingers	of	one	patient	were	affected,	all	 fingers	with	a	
nerve	injury	without	a	gap	were	randomized	to	the	same	treatment	group	in	study	1,	and	all	
fingers	with	a	critical	sized	defect	were	randomized	to	the	same	treatment	group	in	study	2.	
Since	 the	 study	was	designed	as	a	pilot	 study	we	aimed	at	 including	12	nerve	 injuries	per	
group.	The	outcome	of	epineural	suture	with	fibrin	sealant	(study	1)	and	FNC	(study	2)	were	







The	 FNC	 were	 freshly	 constructed	 during	 surgery	 using	 a	 two-compound	 fibrin	 hydrogel	
(Tisseel®	Kit	VH	1.0,	Baxter	SA,	Switzerland).	Tisseel	provides	a	fibrinogen	solution	containing	
fibrinogen	 72-110	 mg/ml,	 factor	 XIII	 0.6-10	 IU/ml,	 plasminogen	 40-120	 mg/ml,	 aprotinin	
synthetic	3000	KIU/ml,	and	a	thrombin	solution	500	IU/ml	with	calcium	chloride	40	μmol/ml.	
The	 fibrinogen	 and	 the	 thrombin	 were	 injected	 from	 two	 separate	 syringes	 through	 one	
head	into	the	desired	site	where	the	fibrinogen	polymerizes	to	fibrin.	The	fibrin	gel	was	filled	
into	 a	 designed	 silicone	 inlay	 of	 a	 developed	medical	 compressor	 around	 a	 stainless-steel	














































Chart	1. Study	design,	patients included,	drop outs and completed follow-ups.
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2.3.	Surgical	Treatment	
All	 surgeries	 were	 performed	 by	 experienced	 microsurgeons.	 Damaged	 nerve	 ends	 were	
resected	as	needed.	In	the	standard	treatment	group	of	study	1	(group	1a),	the	nerve	ends	




2	 (group	2a),	 the	LACN	was	 transplanted	as	autograft.	The	proximal	and	distal	nerve	ends	
were	each	adapted	with	2	epineural	sutures.	 In	 the	treatment	group	2b,	 the	proximal	and	
distal	nerve	ends	were	inserted	at	each	end	for	2	mm	into	the	fibrin	conduit	and	attached	to	






Ambulatory	 follow-up	 assessments	 of	 patients	 were	 carried	 out	 at	 2	 weeks,	 3,	 6,	 and	 12	
months	after	peripheral	nerve	repair.	At	every	clinical	visit,	we	assessed	scar	quality	and	pain	
on	 a	 visual	 analogue	 scale	 (VAS),	 satisfaction	 scores	 according	 to	 the	 Michigan	 Hand	
Outcomes	 Questionnaire,	 surgical	 site	 infection	 according	 to	 CDC	 (Centers	 for	 Disease	
Control	and	Prevention),	complication	rate	according	to	the	Dindo-Clavien	classification	[228]	
and	adverse	events	(AEs).	At	3,	6,	and	12	months	after	surgery,	we	additionally	performed	





No.	 NC12776).	 The	 discriminator	 was	 applied	 longitudinally	 to	 the	 finger	 at	 the	 palmar	
fingertip	for	at	least	three	seconds	in	a	random	manner.	The	patient	was	asked	to	close	the	
eyes	and	indicate	perception	by	saying	“one”	or	“two”,	when	perceiving	one	or	two	points,	
respectively.	 In	 case	 of	 an	 inaccurate	 response,	 the	 distance	 between	 the	 points	 was	
increased,	 in	 order	 to	 define	 the	 smallest	 detectable	 2-point	 discrimination.	 The	 outcome	
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performed	over	 the	entire	palmar	 length	of	 the	 respective	digital	nerve.	The	 filament	was	
applied	at	a	force	where	it	started	to	bend	for	a	total	of	three	times.	The	patient	was	asked	
to	 close	 the	 eyes	 and	 indicate	 perception	 of	 the	 touch	 by	 saying	 “yes”.	 The	 next	 higher	





















based	 on	 the	 patients’	 perception	 of	 improvement	 or	 impairment	 of	 nerve	 and	 wound	
regeneration.	 The	 MHQ	 is	 a	 37-item	 questionnaire	 covering	 the	 following	 six	 domains:	
overall	 hand	 function	 (OHF),	 activities	 of	 daily	 living	 (ADL),	 pain,	work	 performance	 (WP),	
aesthetics	and	satisfaction	with	hand	function.	The	scoring	method	was	developed	by	Chung	
et	al.	[233].	Each	item	is	scored	on	a	scale	between	1	and	5,	and	the	sum	for	each	category	is	
converted	 into	a	scale	 ranging	 from	0	 to	100.	A	high	score	 indicates	better	hand	 function,	
except	 for	the	subscale	“pain”,	where	a	high	score	refers	to	more	pain.	The	domains	OHF,	
ADL,	 aesthetics,	 and	 patient	 satisfaction	 contain	 questions	 for	 the	 right	 and	 left	 hand	






Sensory	 orthodromic	 nerve	 conduction	 studies	 (NCS)	 of	 the	 affected	 digital	 nerve	 were	
performed	 using	 surface	 electrodes.	 Sensory	 nerve	 conduction	 velocity	 (m/s)	 (NCV)	 and	
peak-to-peak	 amplitude	 of	 the	 sensory	 nerve	 action	 potential	 (µV)	 (SNAP)	were	 assessed.	
Independently	of	the	patient’s	age,	normative	values	were	defined	for	digital	nerves	derived	
from	the	median	or	 the	ulnar	nerve	based	on	 the	 textbook	published	by	Stöhr	and	Pfister	







	 Median	nerve	 Ulnar	nerve	 Score	
Normative	values	sensory	NCV	 ≥47m/s	 ≥45m/s	 1	
Normative	values	peak-to-peak	SNAP	 ≥7µV	 ≥6µV	 1	
Reduced	values	sensory	NCV	 <47m/s	 <45m/s	 2	
Reduced	value	peak-to-peak	SNAP	 <7µV	 <6µV	 2	





Based	 on	 the	 non-inferiority	 hypothesis	 which	 predicts	 no	 statistical	 difference	 in	 clinical	
outcomes	and	patient	satisfaction	for	the	experimental	treatment	groups	of	studies	1	and	2	










For	 this	 manuscript	 data	 of	 36	 patients	 with	 46	 nerve	 injuries	 were	 analyzed.	 12	 nerve	
injuries	each	were	included	in	groups	1a,	1b	and	2b,	while	in	group	2a	only	10	nerve	injuries	
could	be	examined	up	to	now.	1	nerve	injury	in	group	1a,	2	nerve	injuries	in	group	2a	and	3	
nerve	 injuries	 in	 group	 2b	 have	 not	 finished	 the	 study	 yet.	 After	 inclusion	 of	 another	 2	






















The	s2PD	measured	at	 the	healthy	hand	usually	 resulted	 in	values	of	3	–	6	mm	(S4	or	S3;	
data	 not	 shown).	 S3	 at	 the	 non-affected	 hand	 was	 mainly	 obtained	 for	 patients	 with	
calloused	 skin.	 In	 study	 1,	 no	 differences	 were	 found	 between	 the	 standard	 and	 the	
experimental	group	throughout	the	follow-up	assessments	(Figure	2	and	Table	4).	In	study	2,	
group	2b	showed	enhanced	sensory	recovery	at	3	and	6	months	after	surgery	compared	to	












































Figure 1. Age distribution of the studie‘s patient
population at the time of the surgery. The bars
represent the number of patients in a certain
age category (in years).
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significant	differences	were	 found	 for	 study	1	between	group	1a	and	group	1b	with	mean	
scores	of	4.45	±	0.52	 for	group	1a,	and	4.33	±	0.78	 for	group	1b.	 In	study	2,	experimental	
group	 2b	 reached	 a	 significantly	 better	 sensory	 outcome	 compared	 to	 standard	 group	 2a	
with	mean	scores	of	3.63	±	0.52	for	group	2a,	and	4.33	±	0.71	for	group	2b.	Details	for	the	








Figure 2. Data for the static 2-point discrimination (s2PD) test at 3,
6, and 12 months‘ (m) follow-up. The bars represent the mean ±
SD of the score (ranging from S1 to S4) obtained by each study
group. A high score is indicative for an improved functional






















	 3	months	 6	months	 12	months	
Group	1a	 2.00	±	0.95	 2.89	±	0.33	 3.00	±	0.63	
Group	1b	 2.09	±	1.04	 2.80	±	0.79	 3.33	±	0.49	
Group	2a	 1.57	±	0.79	 2.33	±	0.52	 3.00	±	0.76	







	 3	months	 6	months	 12	months	
Group	1a	 3.25	±	1.36	 4.33	±	0.50	 4.45	±	0.52	
Group	1b	 4.00	±	1.00	 4.40	±	0.70	 4.33	±	0.78	
Group	2a	 2.86	±	1.35	 3.57	±	0.53	 3.63	±	0.52	








	 2	weeks	 3	months	 6	months	 12	months	
Group	1a	 1.25	±	1.49	 1.92	±	2.19	 0.11	±	0.33	 0.18	±	0.60	
Group	1b	 1.40	±	1.43	 0.91	±	1.51	 0.10	±	0.32	 0.25	±	0.62	
Group	2a	 1.17	±	0.98	 1.29	±	0.95	 0.86	±	0.69	 1.00	±	1.69	
























evaluation	 revealed	higher	pain	 scores	 for	 group	2b	 compared	 to	group	2a	 throughout	all	
follow-up	assessments	 (Table	6).	Final	scores	at	12	months	were	0.18	±	0.60	 for	group	1a,	
0.25	 ±	 0.62	 for	 group	 1b,	 1.00	 ±	 1.69	 for	 group	 2a,	 and	 1.89	 ±	 2.09	 for	 group	 2b.	 No	
statistically	significant	differences	were	 found	between	the	standard	and	the	experimental	
groups	of	studies	1	or	2.	
Figure 3. Data for the Semmes Weinstein Monofilament (SWM)
test at 3, 6, and 12 months‘ (m) follow-up. The bars represent the
mean ± SD of the score (ranging from S1 to S5) obtained by each
study group. A high score is indicative for an improved functional
outcome. Significant differences are indicated as P < 0.05*, P <
























	 3	months	 6	months	 12	months	
Group	1a	 2.00	±	0.95	 2.89	±	0.33	 3.00	±	0.63	
Group	1b	 2.09	±	1.04	 2.80	±	0.79	 3.33	±	0.49	
Group	2a	 1.57	±	0.79	 2.33	±	0.52	 3.00	±	0.76	







	 3	months	 6	months	 12	months	
Group	1a	 3.25	±	1.36	 4.33	±	0.50	 4.45	±	0.52	
Group	1b	 4.00	±	1.00	 4.40	±	0.70	 4.33	±	0.78	
Group	2a	 2.86	±	1.35	 3.57	±	0.53	 3.63	±	0.52	








	 2	weeks	 3	months	 6	months	 12	months	
Group	1a	 1.25	±	1.49	 1.92	±	2.19	 0.1 	 	0.33	 0.18	±	0.60	
Group	1b	 1.40	±	1.43	 0.91	±	1.51	 0.10	±	0.32	 0.25	±	0.62	
Group	2a	 1.17	±	0.98	 1.29	±	0.95	 0.86	±	0.69	 1.00	±	1.69	


















Figure 4. Data for the Visual analogue Scale (VAS) for pain
assessment at 2 weeks‘ (w), 3, 6, and 12 months‘ (m) follow-up. The
bars represent the mean ± SD of the score (ranging from 1 to 10)
obtained by each study group. A high score is indicative for
increased pain sensation. No significant differences are observed.




















	 3	months	 6	months	 12	months	
Group	1a	 2.00	±	0.95	 2.89	±	0.33	 3.00	±	0.63	
Group	1b	 2.09	±	1.04	 2.80	±	0.79	 3.33	±	0.49	
Group	2a	 1.57	±	0.79	 2.33	±	0.52	 3.00	±	0.76	







	 3	months	 6	months	 12	months	
Group	1a	 3.25	±	1.36	 4.33	±	0.50	 4.45	±	0.52	
Group	1b	 4.00	±	1.00	 4.40	±	0.70	 4.33	±	0.78	
Group	2a	 2.86	±	1.35	 3.57	±	0.53	 3.63	±	0.52	








	 2	weeks	 3	months	 6	months	 12	months	
Group	1a	 1.25	±	1.49	 1.92	±	2.19	 0.11	±	0.33	 0.18	±	0.60	
Group	1b	 1.40	±	1.43	 0.91	±	1.51	 0.10	±	0.32	 0.25	±	0.62	
Group	2a	 1.17	±	0.98	 1.29	±	0.95	 0.86	±	0.69	 1.00	±	1.69	

























follow-up	 assessments	 at	 6	 and	 12	 months,	 no	 significant	 score	 differences	 were	 found,	








A	 statistically	 meaningful	 evaluation	 of	 the	 data	 was	 not	 possible	 due	 to	 a	 low	 patient	
engagement.	 Generally,	 we	 observed	 that	 sensory	 nerve	 conduction	 and	 conduction	
amplitude	can	be	deduced	for	all	tested	patients	after	12	months,	in	contrast	to	outcomes	at	
3	 months	 or	 6	 months	 where	 NCV	 and	 SNAP	 for	 certain	 nerves	 could	 not	 be	 detected	
(Supplementary	 figure	2).	Supplementary	 table	3	shows	 the	measurements	 for	each	nerve	
injury.	 Patients	 generally	 seemed	 to	 experience	 an	 improvement	 of	 sensory	 nerve	
conduction	velocity	and	amplitude	over	the	follow-up	period.		
Figure 5. Data for the Michigan Hand outcome Questionnaire
(MHQ) at 2 weeks‘ (w), 3, 6, and 12 months‘ (m) follow-up. The
bars represent the mean ± SD of the score (ranging from 1 to 100)
obtained by each study group. A high score is indicative for higher
patient‘s satisfaction. Significant differences are indicated as P <
0.05*, P < 0.01** and P < 0.001***.




























subcategories	 Group	 2	weeks	 3	months	 6	months	 12	months	
	Total	
1a	 46.6	±	7.1	 75.1	±	15.7	 91.7	±	6.4	 90.4	±	11.7	
1b	 64.7	±	16.7	 84.8	±	11.8	 91.3	±	6.2	 95.7	±	3.2	
2a	 46.1	±	11.1	 82.0	±	8.2	 86.3	±	7.5	 85.7	±	15.0	
2b	 49.1	±	16.9	 68.6	±	24.2	 80.0	±	17.1	 81.3	±	13.9	
OHF	
1a	 35.0	±	15.4	 65.0	±	23.7	 81.7	±	14.1	 83.2	±	15.0	
1b	 57.5	±	17.7	 79.1	±	17.9	 86.5	±	9.4	 90.0	±	7.7	
2a	 40.0	±	25.7	 70.0	±	16.6	 78.6	±	3.8	 81.3	±	16.2	
2b	 50.0	±	14.7	 55.0	±	21.4	 70.6	±	13.6	 79.4	±	15.1	
ADL	
1a	 16.9	±	23.3	 84.4	±	15.5	 93.1	±	8.4	 89.0	±	20.4	
1b	 66.2	±	23.5	 88.9	±	10.8	 94.6	±	5.9	 96.7	±	5.0	
2a	 37.2	±	23.0	 90.2	±	12.6		 93.8	±	4.3	 91.7	±	10.2		
2b	 33.0	±	18.3	 69.9	±	25.2	 77.5	±	17.6	 79.2	±	17.8	
WP	
1a	 3.8	±	5.2	 57.5	±	29.1	 96.1	±	4.9	 88.6	±	20.5	
1b	 37.0	±	33.0	 76.8	±	24.3	 89.5	±	14.6	 98.8	±	3.1	
2a	 18.6	±	24.8	 87.9	±	7.6	 92.1	±	9.1	 85.0	±	22.7	
2b	 22.1	±	33.1	 62.1	±	38.4	 83.3	±	25.6	 82.2	±	20.8	
Pain	
1a	 29.4	±	25.4	 13.0	±	17.0	 1.1	±	3.3	 2.7	±	9.0	
1b	 23.0	±	20.3	 8.2	±	13.5	 4.5	±	12.6	 2.9	±	7.5	
2a	 32.9	±	17.0	 20.0	±	14.1	 11.4	±	10.7	 11.3	±	20.3	
2b	 33.6	±	22.7	 17.9	±	20.2	 15.6	±	24.7	 22.2	±	17.7	
Aesthetics	
1a	 95.3	±	6.5	 97.5	±	6.0	 97.2	±	3.3	 98.9	±	2.5	
1b	 89.4	±	11.0	 96.0	±	4.2	 93.8	±	7.8	 96.4	±	7.8	
2a	 68.8	±	16.5	 92.0	±	4.7	 93.8	±	16.5	 93.8	±	17.7	
2b	 79.5	±	19.0	 79.5	±	28.8	 87.5	±	13.6	 91.7	±	18.2	
	Satisfaction	
1a	 58.3	±	17.1	 59.2	±	29.2	 83.3	±	9.3	 85.6	±	13.6	
1b	 61.3	±	24.5	 76.1	±	21.2	 87.9	±	10.3	 95.1	±	5.0	
2a	 45.2	±	22.2	 72.0	±	13.3	 85.1	±	12.7	 86.5	±	15.1		










patients	 of	 the	 standard	 treatment	 group	1a,	who	 received	 epineural	 sutures	 only.	 In	 the	
SWM	test	as	well	as	concerning	the	answers	of	the	MHQ,	group	1b	scored	more	favorably	
than	group	1a	until	3	months	after	surgery.	In	addition,	pain	perception	on	the	VAS	in	group	
1b	 was	 lower	 at	 3	 months.	 No	 difference	 in	 performance	 was	 seen	 for	 the	 s2PD.	 These	
results	 indicate	 an	 enhancement	 of	 early	 nerve	 regeneration	 in	 group	 1b	which	might	 be	
attributed	to	the	increased	tensile	strength	at	the	coaptation	site	thanks	to	the	fibrin	sealant	
as	reported	earlier	[39,40].	Assessments	at	6	and	12	months	resulted	in	similar	outcomes	for	
all	 parameters	 (s2PD,	 SWM	 test	 and	 MHQ)	 in	 both	 groups,	 and	 both	 groups	 reported	 a	
mostly	 complete	 pain	 relief	 from	 6	 months	 on.	 These	 outcomes	 imply	 equivalent	 nerve	
regeneration	for	standard	and	experimental	treatment	strategies	for	non-gap	nerve	injuries	
in	 the	 long	 term.	Hereby,	our	 results	are	 line	with	other	 reports	observing	 that	 fibrin	glue	
does	 not	 inhibit	 the	 nerve	 regeneration,	 and	 is	 a	 suitable	 biomaterial	 to	 be	 used	 for	
peripheral	nerve	 repairs	 [32,239,240].	 Simultaneously,	our	data	 supports	 the	 statement	of	
Mermans	 et	 al.	 [230],	 that	 follow-up	 is	 positively	 correlated	 with	 sensory	 outcome	 after	
digital	nerve	repair.	According	to	these	authors,	a	stable	level	of	sensibility	 is	reached	by	6	
months,	which	could	be	the	time	needed	for	functional	reorganization.	A	multicenter	study	
with	 formal	 cohort	 size	 calculation	might	 allow	 to	 disclose	 significant	 differences	 in	 early	
functional	nerve	recovery	between	the	standard	and	the	experimental	treatment	group.		
In	 study	 2,	 we	 compared	 treatment	 outcomes	 of	 the	 experimental	 fibrin	 conduit	
group	2b	with	the	standard	nerve	autograft	group	2a.	Sensory	recovery	in	the	experimental	
group	2b	was	enhanced	at	3	months	for	the	s2PD	test	as	well	as	the	SWM	test	compared	to	
the	 standard	 group	 2a,	which	 implies	 improved	 early	 nerve	 regeneration	 for	 nerve	 repair	
with	FNC.	The	outcome	of	group	2a	balanced	out	in	the	s2PD	test	to	the	level	of	group	2b,	
but	scores	for	pressure	sensation	tested	with	the	SWM	were	significantly	better	in	group	2b	
at	 12	months	 after	 surgery.	 This	 is	 a	 novel	 finding,	 since	 nerve	 conduits	 tend	 to	 show	 an	
inferior	 regenerative	 potency	 compared	 to	 nerve	 autografts	 [232].	 In	 contrast	 to	 clinical	
outcomes,	pain	reported	scores	were	higher	in	group	2b	compared	to	group	2a	throughout	
the	follow-ups,	in	line	with	a	lower	overall	patient	satisfaction	in	the	MHQ	for	group	2b	at	3	
months	 after	 surgery.	 However,	 the	 VAS	 score	 might	 be	 biased	 due	 to	 undifferentiated	
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answer	options.	Patients	usually	reported	unpleasant	sensations	such	as	tingling,	burning,	a	
buzzing	 “electric”	 feeling,	 or	 numbness	 more	 commonly	 than	 actual	 pain.	 Unfortunately,	
these	 sensations,	 which	might	 be	 associated	 to	 incomplete	 nerve	 regeneration,	 were	 not	
documented	 in	 this	 study.	 Thus,	 the	 exact	 reasons	why	 sensations	 of	 nerve	 irritation	 are	
slightly	 more	 frequent	 in	 group	 2b	 remain	 to	 be	 investigated.	 Considering	 the	 statistical	
insignificance	 of	 the	 differences	 observed,	 non-inferiority	 of	 the	 experimental	 treatment	
with	FNC	compared	to	the	standard	autograft	treatment	for	bridging	10	mm	nerve	gaps	can	
be	concluded.	Moreover,	nerve	repair	with	fibrin	conduit	has	several	undeniable	advantages:	
no	 sacrifice	 of	 a	 healthy	 nerve,	 no	 second	 surgery	 site,	 easier	 technique,	 and	 reduced	
surgery	 time	and	 thus	cost	effectiveness.	Therefore,	nerve	 repair	with	FNC	might	not	only	
present	 a	 viable	 alternative,	 but	 a	 new	 treatment	 strategy	 for	 short	 nerve	 gaps,	 as	 also	
suggested	by	Paprottka	et	al.	[10].			
The	experimental	treatments	of	both,	study	1	and	2	showed	tendencies	towards	resulting	in	
a	more	 favorable	 sensory	 outcome	 than	 standard	 treatments.	 Age	 has	 been	 discussed	 to	
strongly	 influence	 the	 sensory	 regeneration	 [10,230,241,242].	 Since	 the	mean	 age	 of	 the	
patients	 in	 both	 experimental	 groups	was	 higher	 than	 the	 age	 of	 the	 patients	 in	 the	 two	
standard	groups,	this	bias	can	be	excluded.	Nevertheless,	the	present	study	was	created	as	
pilot	clinical	trial,	and	the	small	number	of	patients	per	group	(n	=	12)	may	not	allow	a	final	
statement	 on	 the	 true	 equivalence	 or	 differences	 between	 the	 treatment	 strategies.	
Moreover,	 the	 practice	 to	 allow	 the	 randomization	 and	 inclusion	 of	 the	 same	 patient	 for	
multiple	nerve	injuries	in	different	fingers	might	have	led	to	a	bias	in	the	functional,	but	also	
in	 the	 patients’	 satisfaction	 outcome,	 assuming	 that	 the	 outcome	 largely	 depends	 on	 the	
patients’	compliance	to	therapy,	expectations	and	resources.	In	addition,	post-surgical	care	
was	not	standardized,	with	patients	 following	 regular	 rehabilitation	plans	and	patients	not	
receiving	rehabilitation	at	all.	In	study	2,	only	short	nerve	gaps	up	to	10	mm	were	evaluated	
for	 reasons	of	 comparability.	 The	performance	of	 fibrin	 conduits	 in	 long	nerve	 gaps	 could	
thus	 not	 be	 assessed.	 However,	 the	 purpose	 of	 this	 pilot	 clinical	 study	 was	 to	 provide	
preliminary	 data	 for	 a	 subsequent	multicenter	 study	with	 a	 formal	 cohort	 size	 calculation	
through	which	results	of	higher	validity	could	be	obtained.	The	introduction	of	the	FNC	into	
a	clinical	setting	 is	a	premiere	and	has	yielded	very	promising	outcomes.	Moreover,	 this	 is	
the	first	clinical	study	evaluating	an	innovative	nerve	conduit	which	provides	not	only	clinical	
functional	 outcomes,	 but	 also	 data	 on	 patient	 satisfaction,	 pain	 sensation,	 and	 on	 nerve	
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conduction.	 Compared	 to	 other	 equally	 promising	 bridging	 options	 in	 the	 field	 such	 as	
collagen	 conduits	 or	 the	 allograft,	 fibrin	 conduits	 present	 several	 advantages:	 with	 the	
appropriate	molds,	 the	 surgeon	 can	 relatively	 spontaneously	 constitute	 fibrin	 gel	 conduits	








However,	 the	 optimization	 of	 empty	 fibrin	 conduits	 is	 an	 active	 field	 of	 research.	 Several	
interesting	 concepts	 have	 been	 developed,	 since	 a	 wide	 range	 of	 experimental	 fibrin	





Experimental	 treatment	options,	 i.e	 the	epineural	 suture	combined	with	 fibrin	sealant	and	
the	 fibrin	 nerve	 conduit,	 enhanced	 early	 sensory	 recovery	 and	 presented	 a	 non-inferior	
performance	 in	 the	 long-term	compared	to	standard	 treatment	options	 for	no	gap	and	10	
mm	nerve	gap	 injuries.	 	 This	was	observed	by	 functional	 clinical	outcome	parameters	and	
patient	satisfaction	levels	at	12	months	after	surgery.	A	multicenter	study	with	formal	cohort	
size	 calculation	would	allow	 to	draw	a	 final	 conclusion	on	 the	equivalence	or	 the	possible	









Authors	 contribution	 statement:	D.K.	 supervised	 the	 research	 project;	 K.P.,	M.T.,	M.M.S.	
and	B.D.	conducted	the	study;	K.P.,	M.T.,	M.M.S.,	D.K.,	D.S.	and	C.O.	organized	the	database;	
K.P.	and	M.T.	performed	the	statistical	analysis;	K.P.	wrote	the	first	draft	of	the	manuscript;	


















































11 – 15 mm










































11 – 15 mm




















11 – 15 mm




















11 – 15 mm


































































Supplementary figure 1. Data for the static 2-Point Discrimination (s2PD) test and the Semmes Weinstein Monofilament (SWM) test
at 3, 6, and 12 months‘ follow-up. The bars represent the number of nerves showing the sensory recovery as labelled in the











1a	 1	 2	 5	 4	
1b	 1	 3	 3	 4	
2a	 -	 1	 2	 4	
2b	 2	 2	 1	 2	
6	months	
1a	 -	 8	 1	 -	
1b	 2	 4	 4	 -	
2a	 -	 2	 4	 -	
2b	 3	 5	 1	 1	
12	months	
1a	 2	 7	 2	 -	
1b	 4	 8	 -	 -	
2a	 2	 4	 2	 -	
2b	 5	 2	 1	 1	
	











































1a	 2	 4	 3	 1	 2	
1b	 5	 1	 5	 -	 -	
2a	 -	 3	 2	 -	 2	
2b	 3	 1	 -	 1	 1	
6	months	
1a	 3	 6	 -	 -	 -	
1b	 5	 4	 1	 -	 -	
2a	 -	 4	 3	 -	 -	
2b	 1	 5	 3	 -	 -	
12	months	
1a	 5	 6	 -	 -	 -	
1b	 6	 4	 2	 -	 -	
2a	 -	 5	 3	 -	 -	












































































































































































Supplementary figure 2. Data for the electrophysiological measurements at 3, 6, and 12 months‘ follow-up for sensory nerve
conduction velocity (NCV) and amplitude of the sensory nerve action potential (SNAP). The bars represent the number of nerves
showing normal, reduced or not deducible values for each study group.
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DISCUSSION	AND	OUTLOOK	
The	 work	 completed	 during	 this	 MD-PhD	 thesis	 aimed	 at	 investigating	 innovative	 and	
translational	 treatment	strategies	 for	peripheral	nerve	repair	and	regeneration	 in	different	
experimental	settings.	We	focused	on	following	three	subjects:	1)	new	approaches	in	stem	
cell-based	therapies	by	investigating	the	neurotrophic	potency	of	ASC	in	response	to	specific	
growth	 factor	 stimuli,	 2)	 the	 influence	 of	 the	 stem	 cell	 delivery	 route,	 i.e.,	 FNC	 assisted	
intramural	vs.	intraluminal	ASC-loading	on	early	nerve	regeneration,	and	3)	translation	of	the	




conducted	 an	 in	 vitro	 study	where	we	 analyzed	 the	neurotrophic	 effect	 of	NGF-	 or	VEGF-
stimulated	 ASC’s	 conditioned	medium	 (CM)	 on	 a	 chicken	 embryonic	 dorsal	 root	 ganglion	
(DRG)	model.	Subsequently,	we	translated	the	findings	in	vivo	on	a	10	mm	sciatic	nerve	gap-
model	 in	 rats,	 where	 we	 also	 studied	 two	 approaches	 of	 stem	 cell	 delivery,	 by	 either	
intramural	 or	 intraluminal	ASC-loading	of	 fibrin	 nerve	 conduits.	 In	 the	 second	manuscript,	
we	provided	a	comparative	assay	 for	 the	 impact	of	six	different	NTF,	 i.e.	NGF,	BDNF,	NT3,	
NT4,	 GDNF	 and	 CNTF,	 on	 the	 neurotrophic	 potency	 of	 ASC	 in	 vitro	 and	 studied	 the	
regenerative	events	taking	place	in	the	ASC	and	neuronal	cells.	In	the	third	manuscript,	we	
hypothesized	 non-inferior	 outcomes	 for	 two	 experimental	 nerve	 repair	 strategies,	 i.e.	
epineural	 suture	with	 fibrin	sealant	or	 fibrin	conduit,	as	compared	to	 their	 respective	gold	






several	 limitations,	 hindering	 their	 successful	 translation	 into	 a	 clinical	 context.	 Given	 the	
neurotrophic	 effect	 shown	 for	 ASC	 [104–106],	 and	 the	 fact	 that	 they	 express	 receptor	
binding	 sites	 for	NTF	 [103,160–162]	 and	 are	 able	 to	 secrete	 a	 range	 of	molecular	 growth	
signals	 [98,100],	we	hypothesized	 impactful	change	 in	 the	ability	of	ASC	 to	support	axonal	
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regeneration	 in	 response	 to	 growth	 factors’	 stimuli.	 Indeed,	 we	 were	 able	 to	 show	 an	
important	 enhancement	 of	 axonal	 regeneration	 in	 vitro	 and	 in	 vivo	 for	 experimental	
conditions	 involving	 NTF-stimulated	 ASC.	 Striking	 was	 also	 the	 consistent	 superiority	 in	
axonal	 outgrowth	 of	 NT3-stimulated	 ASC	 compared	 to	 other	 NTF.	 In	 line,	 we	 observed	
several	 significantly	 up-regulated	 regenerative	 mechanisms	 at	 a	 transcriptional	 and	





question	 rises,	 how	 one	 can	 be	 sure,	 that	 the	 neurotrophic	 effect	 is	 not	 mainly	 to	 be	
attributed	 to	 the	 addition	 of	 exogenous	 NTF,	 since	 they	 exert	 a	 more	 potent	 effect	 in	
transcriptional	and	proteomic	experiments	than	ASC	alone.		
Characterization	of	 the	changing	 secretome	of	 stimulated	ASC,	 the	 identification	of	
the	respective	upregulated	receptors	on	ASC	and	neuronal	cells,	as	well	as	the	assessment	of	
the	neuronal	cell	viability	and	survival	after	treatment	would	provide	more	insights	into	the	
above-mentioned	 topic.	 However,	 a	 clear	 enhancement	 of	 the	 neuroregenerative	 events	
taking	 place	 upon	 treatment	 with	 NT3-stimulated	 ASC	 compared	 to	 treatment	 with	 NT3	
alone	was	demonstrated.	These	observations	indicate	the	enhanced	trophic	potency	of	NT3-
stimulated	 ASC.	 Furthermore,	 the	 distinct	 influence	 of	 different	 NTF	 on	 the	 axonal	
outgrowth	 from	 DRG-explants	 as	 shown	 in	 our	 in	 vitro	 assay	 might	 encourage	 further	
investigations	 on	 the	 joint	 impact	 of	 multiple	 NTF,	 since	 regenerative	 cells	 experience	
stimulation	by	numerous	signals	at	the	injury	site	[22,73].	Also	a	similar	comparative	assay	
using	spinal	cord	explants	might	further	improve	the	understanding	of	the	distinct	effects	of	
NTF	 on	 different	 cell	 populations,	 since	 motor	 and	 sensory	 neurons	 react	 differently	 to	
axotomy,	growth	environment	and	treatment	[243].	For	our	in	vitro	axonal	outgrowth	assay,	
co-culture	with	 a	 trans-well	 system	might	 have	 allowed	 further	 insides	 on	 the	 interaction	










site.	 Fibrin	 gel	 provides	 a	 reliable	 scaffold	 where	 cells	 are	 able	 to	 adhere,	 spread	 and	
proliferate	[112–114].	However,	the	most	favorable	stem	cell	delivery	route	in	FNC	has	not	
been	 investigated	 yet.	 Thus,	we	evaluated	 two	previously	 applied	delivery	 techniques,	 i.e.	
intramural	 [116]	 versus	 intraluminal	 [115]	 ASC-loading	 of	 FNC	 in	 vivo.	 The	 results	 suggest	
that	intramural	delivery	of	NGF-stimulated	ASC	in	FNC	promoted	better	axonal	regeneration	
than	 the	 respective	 intraluminal	 delivery.	As	 discussed	 in	manuscript	 1,	 the	 differences	 in	
regenerative	outcomes	may	be	due	to	the	variable	density	of	transplanted	cells	within	the	
hydrogel	 microenvironment,	 resulting	 in	 high	 concentrations	 of	 local	 growth	 factors.	
However,	the	events	taking	place	after	nerve	injury	involve	up-	but	also	down-regulation	of	
certain	growth	factors	during	the	different	stages	of	nerve	regeneration	[22,73].	Moreover,	
the	 delivery	 of	 neurotrophic	 factors	 at	 high	 concentrations	 has	 been	 shown	 to	 be	
detrimental	 for	 axonal	 regeneration	 [74].	 Thus,	 the	 highly	 enriched	 luminal	
microenvironment	 of	 the	 intraluminal	 delivery	 system	 may	 impede	 the	 speed	 of	 axonal	
regeneration	in	contrast	to	the	intramural	delivery	system.		
Despite	 improved	 neuro-regeneration	 by	 intramural	 delivery	 of	 NGF-stimulated	 ASC,	 the	
outcome	 of	 the	 autograft	 group	 remains	 superior,	 indicating	 a	 clear	 need	 for	 further	
refinement	of	this	concept.	It	 is	not	unlikely	that	transplanted	NTF-stimulated	ASC	face	the	
same	 fate	 as	 transplanted	 SCLC,	 which	 show	 a	 rapid	 reversion	 to	 stem	 cell-like	
characteristics	after	the	withdrawal	of	the	differentiation	medium	as	shown	by	Faroni	et	al.	
[103].	As	suggested	by	the	authors	of	this	paper,	gene	expression	and	protein	level	changes	
in	NTF-stimulated	ASC	after	 a	 period	of	 time	would	 shed	 light	 on	 this	 issue.	 The	question	
remains,	how	 the	enhanced	 regenerative	properties	of	ASC	can	be	maintained.	Under	 the	






Innovative	 and	 translational	 treatment	 alternatives	 for	 the	 surgical	 repair	 of	 peripheral	
nerve	 injuries	are	sought,	 in	order	 to	overcome	the	disadvantages	of	 the	current	standard	
techniques	[1,31].	Since	fibrin	hydrogel	is	an	already	widely	used	and	accepted	biomaterial	
in	the	surgical	practice	[58–60],	 its	application	for	the	peripheral	nerve	repair	 is	of	 interest	
[32,63].	In	order	to	avoid	increased	inflammation	and	fibrosis	at	the	coaptation	site	of	nerve	
ends,	the	approach	of	reduced	number	of	epineural	sutures	with	additional	fibrin	sealant	for	
improved	 stability	has	been	 suggested	 [40,41].	 Stability	of	 the	 coaptation	 site	might	be	of	
special	 importance	 in	 the	 early	 phase	 of	 nerve	 regeneration,	where	 severed	 axons	 sprout	
and	 engage	 in	 path	 finding	 and	 reconnection	 with	 the	 distal	 nerve	 end.	 Indeed,	 the	




6	 and	 12	 months	 after	 surgery,	 which	 implies	 non-inferior	 nerve	 regeneration	 for	 the	
experimental	treatment	strategy	as	compared	to	the	standard	treatment	for	non-gap	nerve	
injuries	in	the	long	term.	Moreover,	along	with	other	authors,	we	were	able	to	confound	the	




of	 depleted	 co-morbidities.	 Our	 results	 showed	 enhanced	 early	 sensory	 recovery	 for	 the	
experimental	 fibrin	 conduit	 group	 2b	 compared	 to	 the	 standard	 autograft	 group	 2a.	
Surprisingly,	pressure	sensation	tested	with	the	SWM	reached	significantly	better	scores	 in	
group	2b	at	the	final	12	months’	follow-up.	Overall,	non-inferiority	for	the	nerve	repair	with	
fibrin	 conduits	 compared	 to	 the	 nerve	 autograft	 could	 be	 concluded	 due	 to	 otherwise	
statistically	 insignificant	 differences	 in	 treatment	 outcomes.	 A	 (multicentre)	 study	 with	
formal	 cohort	 size	 calculation	would	 allow	 to	 support	 our	 findings	made	 for	 study	 1	 and	
study	2.		
There	 exist	 several	 limitations	 in	 the	 design	 and	 the	 conduct	 of	 the	 study	 as	 discussed	 in	
manuscript	 3,	 which	might	 have	 caused	 a	 bias	 of	 the	 findings	 of	 this	 study.	 Additionally,	
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several	examiners	were	involved	in	the	study,	which	might	have	generated	an	inconsistency	
in	examination	 techniques	of	 clinical	outcomes.	Also	 the	 time	points	of	patient	 follow-ups	
were	 rather	 heterogeneous,	 even	 though	 patients	 were	 asked	 to	 return	 for	 ambulatory	
assessments.	 However,	 in	 strong	 favor	 for	 our	 clinical	 study,	 it	 provides	 a	 wide	 range	 of	
outcome	 parameters,	 i.e.	 clinical	 outcomes,	 patient	 satisfaction	 and	 nerve	 conduction	
studies,	which	is	rarely	found	in	other	comparable	studies.	This	allows	a	more	holistic	view	
on	the	treatment	outcomes.	Since	only	short	nerve	gaps	of	10	mm	length	were	investigated,	
the	performance	of	 fibrin	 conduits	 for	 supporting	 longer	nerve	 gap	 injuries	 remains	 to	be	
investigated.	 In	order	 to	enhance	 the	 supportive	 capacity	of	 fibrin	nerve	 conduits	 also	 for	




This	 MD-PhD	 thesis	 investigated	 innovative	 and	 translational	 treatment	 options	 for	
peripheral	nerve	regeneration	and	repair.	ASC	showed	a	significantly	improved	neurotrophic	
potency	upon	stimulation	with	various	NTF,	in	particular	in	response	to	NT3.	Upregulation	of	
regeneration-associated	 pathways	were	 detected	 in	ASC	 as	well	 as	 in	 sensory	 neurons.	 In	
vivo,	 intramural	 delivery	 of	NGF-stimulated	ASC	 in	 fibrin	 nerve	 conduits	 offered	 improved	
support	 for	 the	early	nerve	 regeneration	 in	comparison	 to	 intraluminal	delivery.	Together,	
these	 findings	provide	new	knowledge	and	possibilities	 for	 the	development	of	ASC-based	
therapies.	Moreover,	a	direct	comparative	overview	over	the	neurotrophic	effect	of	various	
NTF	 is	 given.	 In	 the	 clinical	 context,	 treatment	 of	 patients	 for	 digital	 nerve	 injuries	 with	
epineural	 suture	 and	 fibrin	 sealant	 or	 fibrin	 conduit	 resulted	 in	 improved	 early	 nerve	






and	this	MD-PhD	thesis	has	offered	new	 insights	on	how	an	 improved	 functional	outcome	









injuries	 treated	 with	 conventional	 treatment	 strategies	 has	 made	 clear,	 that	 nerve	
regeneration	 requires	more	 than	 just	 a	 perfect	microsurgical	 approach.	 Co-morbidities	 of	





MD-PhD	studies	 in	 translational	 research.	 I	was	able	 to	perform	 in	vitro	projects	based	on	
tissue	 from	different	 species.	For	 in	vivo	 studies,	 I	 learned	 the	correct	handling	of	 rodents	
and	 investigated	 the	manufacture	 of	 an	 optimized	 fibrin	 conduit	 as	well	 as	 techniques	 of	





only	was	 I	 constantly	 encouraged	 to	 broaden	my	 horizon	 through	 a	 continuous	 literature	
review,	 but	 also	 the	 classes	 I	 attended	 at	 the	 university,	 as	 well	 as	 the	 contact	 and	 the	
discussions	 with	 the	 researchers	 in	 my	 environment	 shaped	 and	 sharpened	 my	 scientific	
understanding.	Thus,	I	am	proud	to	finish	my	PhD	with	three	manuscripts,	which	include	one	
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